ANIL K. AGARWAL MBBS, MD, FACP, FASN, FNKF, FASDIN 2615 E ...

Anil K. Agarwal, MBBS, MD

ANIL K. AGARWAL

MBBS, MD, FACP, FASN, FNKF, FASDIN 2615 E. Clinton Avenue

Fresno, CA 93703 Mobile: 614-783-0325

Email: [email protected] Last updated 10.20.2021

_____________________________________________________________________________________ CURRENT POSITION:

Chief of Medicine, Veterans Administration Central California Health Care System, Fresno, CA 2020-Present Professor of Internal Medicine, University of California San Francisco, Fresno, CA 2020-Present Academy Professor of Internal Medicine, Ohio State University, Columbus, Ohio 2020-Present MEDICAL EDUCATION Fellow, Nephrology, The Ohio State University 1994-96 Resident, Internal Medicine, The Ohio State University 1992-94 Solo practice, Internal Medicine, Meerut, India 1983-92 MD, Internal Medicine, MLB Medical College, Jhansi, India 1980-83 Demonstrator, Internal Medicine, MLB Medical College, Jhansi, India 1982-83 Resident, Internal Medicine, MLB Medical College, Jhansi, India 1981-82 House Officer, Internal Medicine, MLB Medical College, Jhansi, India 1980-81

Internship, Internal Medicine, MLB Medical College, Jhansi and District Hospital, Mathura, India 1979-80

MBBS, MLB Medical College, Jhansi, India 1974-79 ACADEMIC APPOINTMENTS:

Professor, Internal Medicine, University of California San Francisco, Fresno, CA 2020-Present Academy Professor of Medicine, The Ohio State University, Columbus, Ohio 2020-Present Professor, Internal Medicine, The Ohio State University, Columbus, Ohio 2009-2020 Associate Professor of Clinical Medicine, The Ohio State University, Columbus, Ohio 2004-09 Assistant Professor of Clinical Medicine, The Ohio State University, Columbus, Ohio 1996-04 PROFESSIONAL LEADERSHIP POSITIONS AND EXPERIENCE: President, American Society of Diagnostic and Interventional Nephrology 2020-2022 Advisor, Regional Board of International Society of Nephrology for South Asia 2021-2024 Member, Regional Board of International Society of Nephrology for North America and Caribbean 2021-2024 Chair, Interventional Nephrology Workgroup, International Society of Nephrology 2020-2021 Deputy Chair, Interventional Nephrology Workgroup, International Society of Nephrology 2019-2020 President Elect, American Society of Diagnostic and Interventional Nephrology 2018- 2020


President Elect, American Society of Diagnostic and Interventional Nephrology 2018- 2020 Secretary-Treasurer, American Society of Diagnostic and Interventional Nephrology 2016-18 Chair, Finance Committee, American Society of Diagnostic and Interventional Nephrology 2016-18 Chair, Bylaws Committee, American Society of Diagnostic and Interventional Nephrology 2016-18 Chair, Medical Review Board, IPRO, Renal network for Ohio, Kentucky, Indiana 2016-2020 Chair, Education Committee, American Society of Diagnostic and Interventional Nephrology 2012-16 Chief, Nephrology Section, University Hospital East, Columbus, Ohio 2009-2020 Director for Clinical Scholarship, Center for Faculty Advancement Mentorship and Engagement (FAME), The Ohio State University- 2011-2020 Chair, Scholarship of Practice Task Force, The Ohio State University 2011 Director, Clinical Trials Unit, Division of Nephrology 2009-12 Director, Interventional Nephrology Program, The Ohio State University 2004-2020 Medical Director, Clayton Taylor Hemodialysis Unit 2004- 2020 CERTIFICATIONS AND LICENSURES Diplomat American Board of Nephrology 1996-Present Diplomat American Board of Internal Medicine 1995-2015 Board Certified in Internal Medicine in India 1983-Present Ohio Medical Board 1994-Present South Carolina Medical Board 2004-2021 UP Board, India 1980-1996 PRACTICE AFFILIATIONS OSU Wexner Medical Center, 395 W 12th Avenue, Ground Floor, Columbus, OH 43210. 1992-2020 Care Point East, 543 Taylor Avenue, Columbus, OH 43203. 2003-2020 PROFESSIONAL DEVELOPMENT Chair, Clinical Scholarship- FAME The Advisory Board- Emotional Intelligence Workshop PROFESSIONAL MEMBERSHIPS: International Society of Nephrology1994-Present National Kidney Foundation- 1994-Present American Society of Diagnostic and Interventional Nephrology-2002-Present Renal Physicians Association2010-Present Council on Kidney Disease, American Heart Association 2000-2018 Association of American Physicians from India (AAPI)- Life Member Research Member, Center for Integrative Health and Wellness, OSU- 2010-2020


PROFESSIONAL ACTIVITIES: Regional Champion for Home Therapies. Fresenius Medical Care-North America 2020 Advisor, Otsuka Pharmaceuticals 2018-Present Advisor, Cormedix, Inc. 2018 Chair, Medical Advisory Committee, Island Peer Review Organization, Network 9 2016 Member, Forum of ESRD Networks, representing Network 9 2016 Chair, Medical Advisory Committee, NKF of Ohio. 2014 Advisor, Alexion Pharmaceuticals. 2014 Member, Interventional Nephrology Subcommittee of Education Committee, International Society of Nephrology. 2014-16 Chair, Clinical Excellence Subcommittee of Promotion and Tenure Committee, Department of Internal Medicine, Wexner Medical Center, Columbus, Ohio 2013-14 Member, Workgroup on Self Study of Clinical Faculty, Faculty Affairs, Department of Medicine, The Ohio State University. 2013 Member, Task Force on Department of Medicine P&T document revision 2012 Councilor, Education and Programs, American Society of Diagnostic and Interventional Nephrology. 2011-16 Member, Research Committee, American Society of Diagnostic and Interventional Nephrology 2011-16 Member, AP&T committee, College of Medicine, The Ohio State University.2011-14 Educational Ambassador, International Society of Nephrology, 2010 (Russia), 2015 (India), 2016 (India) Member, International Subcommittee, American Society of Diagnostic and Interventional Nephrology. 2010-16 Member, Interventional Nephrology Advisory Group, American Society of Nephrology. 2010-13 Member, Curriculum Subcommittee, American Society of Diagnostic and Interventional Nephrology 2009-16 Faculty-at-Large, OSU Internal Medicine Board of Managers. 2009-10 Ad Hoc Advisor, Hospira Pharmaceuticals 2008-15 Founding Member- Columbus Global Health Initiative. 2007 Member, Clinical Quality Improvement Committee, Department of Internal Medicine. The Ohio State University. 2006-14 Member, AP&T committee, Department of Internal Medicine, The Ohio State University 2006-10 Member, Advisory group on Dialysis, Ohio Board of Nursing. 2006-09 Medical Advisor, National Kidney Foundation of Ohio 2005-14 Member, Clinical Science Committee, American Society of Nephrology 2005-09 Member, Quality Control Committee, University Hospital East, Columbus 2005-08 Member, National Vascular Access Improvement Initiative Advisory Committee, Network 9 and 10. 2003-15 Member, Board of Directors, National Kidney Foundation of Ohio.2007-Present Ad Hoc Member, Advisory Board, Amgen Inc.2001-14 Ad Hoc Member, Advisory Board, Novartis Pharmaceuticals.2002-12

Ad Hoc Member, Renal Advisory Committee, Abbott Laboratories 2000-12


Consultant for Nephrology Key Opinion Leader Group, Shire Pharmaceuticals 2004

Member, Hospital Infection Control Committee, The Ohio State University

Hospital.1998-08

Member, CME Committee of American Association of Physicians from India (AAPI).

1998-99

Medical consultant to Fertilizer Corporation of India. 1986-89

Medical consultant to Life Insurance Corporation of India 1995-92

Medical consultant to State Bank of India 1985-90

EDITORIAL APPOINTMENTS

Regional Editor for North America:

The Open Urology Nephrology Journal published by Bentham Publishers- 2009-

Present

International Journal of Nephrology- 2010- Present

Honorary Editor

InaKidney- Indonzesian Journal of Kidney and Hypertension- 2018-Present

Associate Editor:

Seminars in Dialysis- 2020-Present

Journal of Vascular Access. 2016-17, 2021-Present.


Indian Journal of Nephrology. 2016-2020.

Editorial Board Member:

Clinical Nephrology. 2020-Present.

Borneo Review of Medical Science, Indonesia. 2020-Present

Kidney Self-Assessment Program (KSAP), ASN, 2016-Present

World Journal of Nephrology- 2011-2016

Peritoneal Dialysis- 2011

Seminars in Dialysis- 2009-2016

Member, KRND ESRD/Dialysis review group- 2013

Journal Reviewership

1. Seminars in Dialysis- 2020-Present

2. British Medical Journal Case Reports-2019

3. Surgery: Current Trends & Innovations- 2019

4. Journal of Vascular Access- 2016-Present

5. Cochrane Kidney and Transplant Review-2016

6. Physiology and Behavior- 2015

7. Clinical Journal of American Society of Nephrology- 2015, 2016

8. British Journal of Applied Sciences and Technology- 2014

9. NKF-CME Activity Review: Saulo Klahr Renal Symposium for Primary Care

Practitioners- 2014

10. Clinical Therapeutics- 2013-2018

11. Am J Nephrology- 2013

12. Kidney Research UK's External Referee Panel- 2011-2016


13. American Heart Journal- 2011-2020

14. Clinical and Applied Thrombosis/Hemostasis- 2011

15. Clinical Anatomy- 2011

16. Hemodialysis International 2011-Present

17. Annals of Internal Medicine 2010

18. Advances in Chronic Kidney Disease 2009-Present

19. Annals of Saudi Medicine 2009-Present

20. BioMed Central Nephrology 2009-Present

21. Journal of Critical Care Medicine, 2009

22. Lancet 2009

23. Libertas Academica, New Zealand 2009

24. National Institutes of Health, Ad hoc reviewer 2009- Present

25. The Open Urology and Nephrology Journal published by Bentham Publishers-

2008, Present

26. Kidney International, 2007-Present

27. Pediatric Nephrology, 2007

28. Seminars in Dialysis, 2007-Present

29. Vascular Health and Risk Management (International Society of Vascular Health),

2007

30. Annals of Internal Medicine, 2005

31. Clinical Nephrology, 2005

32. American Journal of Kidney Disease- 2001-Present

33. Journal of American Society of Nephrology- 2003-Present

34. Nephron, 2004, 2009

35. Panelist, Special Review Panel for the Self-Assessment Questions in NephSAP,

published by

American Society of Nephrology, 2004-2008.


36. Southern Medical Journal, 2000-Present

37. Prescriber’s Letter- Editorial Advisory Board, 2003-2008

38. Relevance reviewer for board examination questions for Nephrology Specialty

Board of ABIM

39. Contributor to examination questions, Nephrology Specialty Board of ABIM.

40. Reviewer for national guidelines for dyslipidemia and bone disease for K-DOQI.

41. Reviewer for multiple institutional guidelines.

Ohio State University Guidelines and reviews:

1. Preventing and responding to Iodinated contrast media induced adverse

reactions including contrast associated Acute Kidney Injury (CA-AKI). 2020.

Preventing and Responding to iodinated Contrast Media Induced Adverse

Reactions Including CA-AKI

2. Prevention of Gadolinium-Induced Toxicity in Adults 2017

3. Preventing and Responding to Contrast Induced Nephropathy (CIN) and

Iodinated Contrast Media-Induce Toxicity 2017

4. Radiology Dialysis Catheter Access use guidelines development and review-

2015

5. Iodinated contrast media-induced toxicity guideline 2014

National Guidelines and Publications

Question Author. Kidney Self-Assessment Program (KSAP). American Society of

Nephrology 2015-Present.

Henner D, Agarwal A, Kalantar-Zadeh K, Rankin LI, Singh H, Strassel L. Inpatient

Medical Director Toolkit. Developed by the Forum of ESRD Networks’

Medical Advisory Council (MAC). June 30, 2020.


file:///C:/Users/akaga/Downloads/IMDT%20Combined%202020%200701c.pdf

accessed July 16, 2020.

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

Associate Director of Operations, Division of Nephrology

Director Interventional Nephrology

Director of Clinical Scholarship for FAME

Core Faculty, Nephrology Fellowship

Member, Finance Committee- Nephrology Division

CLINICAL/ QUALITY IMPROVEMENT ACTIVITIES

Fifty percent clinical activities, including inpatient consults, interventional nephrology

procedures and outpatient clinics

EDUCATIONAL ACTIVITIES

Clinical teaching of fellows, residents and students

Yearly lecture on CKD to residents

2-3 lectures in Nephrology Grand Rounds

CME teaching via local, regional, national and international conferences

HONORS AND AWARDS

Distinguished Member, Medical Advisory Committee, National Kidney Foundation.

2018

Best Doctors in America, 2007-Present

Castle Connolly’s Top Doctors, 2014-Present

Distinguished Service Award, ASDIN- 2016


Best NKF Program Service Partner- 2016

National Kidney Foundation Champion- 2013

Teacher of the Year, Division of Nephrology, 2012

International Educational Ambassador to Russia and India ISN

Platinum award to Clayton Taylor Dialysis Unit- 2011

Top Doctor in Columbus, Ohio, 2010, International Association of Internists 2014

Fellow- American Society of Diagnostic and Interventional Nephrology

Fellow- American College of Physicians

Fellow- American Society of Nephrology

Fellow- National Kidney Foundation

National Merit Scholarship (1972-79)

Honors in Social and Preventive Medicine

Honors in Forensic Medicine

Honors in Obstetrics and Gynecology

GRANTS AND CONTRACT AWARDS

Principal Investigator

1. Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data

(SPRINT - EHR). 1R01HL136679-01A1 (Drawz). University of Minnesota. 07/01/17-

06/30/22.

2. A Phase 3, randomized, open-label, active-controlled study evaluating the efficacy

and safety of oral Vadadustat for the maintenance treatment of anemia in subjects with

non-dialysis dependent chronic kidney disease (NDD-CKD) (PRO2TECT -

CONVERSION). Akebia Protocol AKB-6548-CI-0015. 2016-18.

3. A Phase 3, prospective, multicenter, double-blind, randomized, active control study

to demonstrate the safety and effectiveness of Neutrolin® in preventing catheter-

related bloodstream infections in subjects receiving hemodialysis therapy as treatment


for end stage renal disease. CorMedix, Inc. 2016-18.

4. A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the

Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients

(Fibrogen 063) Protocol: 2015W0037. 2015-18.

5. Multicenter, double blind, placebo-controlled study of PRT-201 administered

immediately after radiocephalic arteriovenous fistula creation in patients with chronic

kidney disease. Proteon Therapeutics. 2015-18

6. Outcome of surgical thrombectomy after failure of percutaneous intervention.

Investigator initiated study. 2015.

7. A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the

Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia

in Subjects with End Stage Renal Disease (ESRD) on Stable Dialysis (Fibrogen 064).

Protocol 2015W0038. 2015

8. Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter for Dialysis.

Merit Medical. 2014-16.

9. A phase 2, single blind, randomized, controlled, multi-center study to evaluate the

efficacy and safety of SRM003 (Vascugel) in the treatment of subjects with vascular

injury resulting from arteriovenous graft surgery for hemodialysis access (AVG01-

SRM003). Project No. 60041121. Shire. $8,754 max per subject clinical trial. 2013-17.

10. A phase 2, single blind, randomized, controlled, multi-center study to evaluate the

efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula

maturation and use in subjects undergoing surgery (AVF01-SRM003) 60041120. Shire.

$9,909.82 max per subject clinical trial. 2013-17.

11. A multi-center, longitudinal, observational study of patients with autosomal

dominant polycystic kidney disease (ADPKD) to establish the rate, characteristics, and

determinants of disease progression. Covance 2011-15.

12. Randomized evaluation of efficacy and safety of Ferric carboxymaltose in patients


with iron deficiency anemia and impaired renal function. Luitpold Pharmaceuticals.

Protocol 1VIT09030, 20010-12.

13. A Phase III, randomized, controlled, open label multicenter study of the efficacy

and safety of TRINAM (EG004); AN assessment of primary unassisted patency and

survival of vascular access grafts in hemodialysis patients with end stage renal disease

(The "ADV-VANTAGE" Trial: Adenovirus VEGF Therapy in Vascular Access – Novel

Trinam Against Control Evidence. Protocol 2009R0085, 2009-12.

14. A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the

Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in

Hemodialysis Patients Previously Treated with Epoetin alfa. Protocol AFX01-12, 2008-

10.

15. A multi-center, randomized, double-blind clinical trial to evaluate the safety and

tolerability of 24 weeks treatment with Vildagliptin (50mg qd) versus Sitagliptin 25mg

qd (Januvia) in patients with type 2 diabetes and severe renal insufficiency. Novartis

Pharmaceuticals Protocol CLAF237A23138. 2007-12.

16. A phase 2, randomized, double blind, placebo-controlled, parallel group, fixed dose

study of AMG 223 in subjects with chronic kidney disease on hemodialysis with

hyperphosphatemia. Amgen Protocol 20070664, 2008-11.

17. AFX01-13: A phase 3, randomized, active controlled, open label, multi-center study

of the safety and efficacy of AF37702 injection for the correction of anemia in patients

with chronic renal failure (CRF) not on dialysis and not on erythropoiesis stimulating

agent (ESA) treatment. Affymax, Inc and Takeda Pharmaceutical Company Limited

Protocol. 2008-11.

18. Outcome trial evaluating the efficacy and safety of Norditropin in adult patients on

chronic hemodialysis. Novo Nordisk protocol 2007-10.

19. Prospective, open label, randomized, multicenter study to demonstrate the efficacy

and safety of intravenous RO0503821 for hemoglobin control in patients transitioning


from chronic kidney disease stage 4 through dialysis. Roche Protocol 2007- trial

cancelled.

20. An open label, randomized, multi-center, parallel group non-inferiority study of

subcutaneous injections of RO0503821 given once monthly vs. Darbepoetin alfa given

according to local label in patients with chronic kidney disease who are not on dialysis.

Roche Protocol no. BH20051. 2007- trial cancelled.

21. Evaluation of Cinacalcet therapy to lower cardiovascular events (EVOLVE study).

Amgen. 2006-12.

22. A randomized study of the safety and efficacy of FG-2216 in subjects with renal

anemia not requiring dialysis and not receiving recombinant human erythropoietin.

Fibrogen Inc. Protocol no. FGCL- SM2216-019. 2006-08.

23. A prospective, multinational, multicenter, double blind, randomized, active-

controlled trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril

and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and

mortality in patients with high-risk hypertension. Novartis protocol no. CCIB00212301.

2005.

24. An open-label, single-arm study to assess the safety of Darbepoetin Alfa

manufactured by a serum free

bioreactor technology in subjects with chronic kidney disease. Amgen Protocol no.

20040180. 2005-11.

$117,575

25. A phase III, double blind, placebo controlled, crossover design, multicenter study

of intravenous

Ferumoxytol compared with placebo. Advanced Magnetics Inc. protocol number 62,

745-8. 2005-07.

26. Sensipar Treatment Algorithm to Reach K/DOQI Targets (START) in Chronic

Kidney Disease subjects on


dialysis with secondary hyperparathyroidism. Amgen Protocol no. 20040123. 2004.

27. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Amgen

Protocol no.

20010184. 2004-11.

28. A multicenter, single arm study evaluating de novo once every two week

Darbepoetin Alfa dosing in subjects with chronic kidney disease not receiving dialysis.

Amgen Protocol no. 20030237. 2003.

29. A phase 3, multicenter randomized, placebo-controlled, double-blinded study to

evaluate efficacy of Staph VAX, a bivalent Staphylococcus aureus glycoconjugate

vaccine in adults on hemodialysis. Nabi-1371, 2003.

30. A randomized, double blind, placebo-controlled, multicenter study evaluating de

novo q2w and maintenance qm Darbepoetin alfa dosing in anemia subjects

with chronic renal insufficiency. Amgen protocol 20030153.

31. Treatment strategies to achieve recommended K/DOQI goals in ESRD patients

on Cinacalcet (TARGET).

Amgen Protocol Number AMG 073 20020390.

32. A multicenter, randomized, open-label study to compare the efficacy and safety of

an oral calcimimetic agent AMG 073) when two different vitamin D regimens are

used in subjects with secondary hyperparathyroidism

of end-stage renal disease (ESRD). Amgen Protocol 20020158. 2003.

33. A multicenter, double-blind, randomized parallel group study to evaluate the

effects of Lotrel and Lotensin

HCT on microalbuminuria in mild to moderate hypertensive subjects with type II

DM. Novartis Pharmaceutical Corporation, Protocol CCCIB002FUS12.

2003.

34. A randomized, double blind study comparing Aranesp (darbepoetin alfa) and

recombinant human


erythropoietin (rHuEPO) in the treatment of anemia in African-American subjects

with chronic renal failure

(CRF) receiving hemodialysis. Amgen Protocol 20010125. 2002.

35. A placebo controlled, double blind, multi-center study to assess safety and

efficacy of an oral calcimimetic

agent (AMG 073) in secondary hyperparathyroidism of chronic kidney disease

(hemodialysis and peritoneal

dialysis). Amgen Protocol 20000188. 2002.

36. A multicenter study evaluating once every other week subcutaneous

administration of Aranesp (Darbepoetin

alfa) in subjects with anemia of chronic renal insufficiency. (STAAR study). Amgen

Protocol 20000256. 2002.

37. A study of Darbepoetin Alfa administered once every four weeks in chronic

renal insufficiency

(CRI) subjects with anemia. Amgen Protocol no. 20010212. 2002.

38. A randomized, multicenter, double blind, parallel group study to determine the

safety and efficacy of Lotrel

versus Enalapril in the treatment of hypertension in type 2 diabetics. Novartis

Pharmaceuticals Corporation

Protocol number 00H0125. 2000.

39. A study of Novel Erythropoiesis Stimulating Protein (NESP) in patients with

chronic renal insufficiency. Amgen Protocol 990788. 2000.

Co- Investigator

1. Using the CardioMEMS Hemodynamic Monitor in Patients with ESRD on

Hemodialysis - A Pilot Study (CardioMEMSinHD). St. Jude’s Medical. 2017.

2. A Phase 3b, multi-center, open label trial to evaluate the long term safety of titrated


immediate-release Tolvaptan (OPC 41061, 30mg to 120mg/day, split dose) in

subjects with autosomal dominant polycystic kidney disease (PKD211). 2014.

3. A phase 3b, multi-center, randomized-withdrawal, placebo-controlled, double-blind,

parallel group trial to compare the efficacy and safety of Tolvaptan (45 to

120mg/day, split-dose) in subjects with chronic kidney disease between late stage

2 to early stage 4 due to autosomal dominant polycystic kidney disease (PKD 210).

2014.

4. START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic

Kidney Disease. Amgen 20110226. PI- Samir Parikh, MD. 2013.

5. A Phase 3 Multicenter, Multi-phase, Multi Dose, Prospective, Randomized, Double-

blind, Placebo-controlled Maintenance Study to Investigate the Safety and Efficacy

of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent,

in Subjects with Hyperkalemia. ZS Pharma. PI- Ravish Shah, MD 2013.

6. Effects of two blood pressure goals on arterial stiffness: SPRINT ancillary study.

Cleveland Clinic Foundation. 2010

7. A multi-center pilot study to assess the safety and efficacy of a selective

Cytopheretic Device (SCD) in patients with acute renal failure (ARF). Cytopherex

Protocol ARF 002 2010-12.

8. A 4-Week dose ranging and efficacy trial of KRX-0502 (Ferric Citrate) in patients

with end-stage renal disease (ESRD) following a two-week washout period. KRX-

0502-305. 2010-11.

9. A phase 3, randomized, active-controlled, open label, multi-center study of safety

and efficacy of AF37702 injection for the maintenance treatment of anemia in

hemodialysis patients previously treated with epoetin alfa/AFX01-12. 2008.

10. A phase I/II open label, dose escalation trial to explore the safety and efficacy of

ICL670 in patients with iron overload resulting from hereditary hemochromatosis.

Novartis protocol CICL670A2202, 2006-09.


11. A randomized, double blind parallel group evaluation of usual care plus

Cerivastatin 0.4 mg once daily compared with usual care (placebo) alone in

patients with ESRD new to hemodialysis. Cerivastatin Heart Outcomes in Renal

Disease: Understanding Survival (CHORUS). Bayer Inc. Protocol 100253. 2000.

12. Trial for Preventing Hypertension (TROPHY) study. Astra Zeneca 1999.

13. A study of the antiproteinuric effects of Omapatrilat and Amlodipine in type II

diabetics with

hypertension and microalbuminuria or overt nephropathy. Bristol-Myers-Squibb

protocol CV137- 046, 1998.

14. Efficacy of Candesartan Cilexetil in Hypertensive black patients: A double blind,

randomized,

placebo-controlled parallel-group design study with an open label long-term

extension. Astra-

Merck Inc. protocol 140. 1997.

PUBLICATIONS

Edited books and curriculum

1. Almehmi A. Interventional Nephrology Primer. 2020. Agarwal AK (Editor). For

American Society of Diagnostic and Interventional Nephrology.

2. Henner D, Agarwal A, Kalantar-Zadeh K, Rankin LI, Singh H, Strassel L. Inpatient

Medical Director Toolkit. Forum of ESRD Networks. 2020

3. Ash SR, Narayan R, Agarwal AK, Crabtree JH. Chapter 32. Operative

Considerations for Peritoneal Dialysis Catheter. In Interventional Nephrology. Eds.

Yevzlin A, Salman L, Ramani K, Shaker Q, Vachharajani T, Asif A. Springer. 2020.

4. Agarwal AK, Oza-Gajera B. New Horizons in Dialysis Access. Special issue of

Advances in Chronic Kidney Disease. July 2020.


5. NephSAP: Interventional Nephrology. Eds Agarwal AK, Niyyar VD, Kumbar L.

American Society of Nephrology, July 2018.

6. Peritoneal Dialysis: Types, Procedures and Risks Factors. Eds Agarwal AK, Arif

A, Salman L. Nova Publishers, New York, 2013.

7. Interventional Nephrology. Eds Asif A, Agarwal AK, Yevzlin A, Wu, S, Beathard

G. McGraw Hill. 2012.

8. Internet Journal of Nephrology. Special issue on Dialysis Access Dysfunction.

Guest Eds Yevzlin A, Arif A, Agarwal AK. Internet Journal of Nephrology. Special

issue on Dialysis Access Dysfunction. 2012.

9. Heart Failure Clinics of North America: Anemia and Heart Failure. Eds Agarwal

AK, Singh A, Katz S. New York, Elsevier. July 2010.

10. NephSAP: Vascular Access for Dialysis. Eds Agarwal AK and Arif A. American

Society of Nephrology, Vol 8 (5), September 2009.

11. Textbook of Nephrology for the Asian-Pacific Physicians. 2nd edition. Eds Mandal

A. and Agarwal AK. New Delhi, Jaypee Brothers. 2004.

Chapters in edited books

1. Haddad NJ, Boubes KY, Agarwal AK. Approach to arteriovenous access. In

Yevzlin AS, Asif A, Salman L, Ramani K, Qaqish SS, Vachharajani TJ (Eds).

Interventional Nephrology Principles and Practice, Second Edition. 2021.

Springer.

2. Ash SR, Narayan R, Agarwal AK, Crabtree JH. Operative considerations

for peritoneal dialysis catheter. In Yevzlin AS, Asif A, Salman L, Ramani K,

Qaqish SS, Vachharajani TJ (Eds). Interventional Nephrology Principles and

Practice, Second Edition. 2021. Springer.

3. Boubes KY, Haddad NJ, Agarwal AK. Approach to a patient with non-

maturing AV fistula. In Yevzlin AS, Asif A, Salman L, Ramani K, Qaqish SS,


Vachharajani TJ (Eds). Interventional Nephrology Principles and Practice,

Second Edition. 2021. Springer.

4. Asif A, Ahmed N, Agarwal AK. Approach to a patient with pseudoaneurysm.

In Yevzlin AS, Asif A, Salman L, Ramani K, Qaqish SS, Vachharajani TJ

(Eds). Interventional Nephrology Principles and Practice, Second Edition.

2021. Springer.

5. Pang S.C., Tan C.S., Agarwal A., Wu S. (2021) Non-tunneled Hemodialysis

Catheter. In: Wu S., Kalva S., Park H., Tan C.S., Beathard G.A. (eds)

Dialysis Access Management. Springer, Cham. https://doi.org/10.1007/978-

3-030-52994-9_20

6. Agarwal A, Rankin L. Procedures Related to Dialysis Including Vascular

Access. In Henner D, Agarwal A, Kalantar-Zadeh K, Rankin LI, Singh H,

Strassel L. (Eds). Inpatient Medical Director Toolkit. Forum of ESRD Networks.

2020

7. Agarwal A. Education in the inpatient dialysis unit. In Henner D, Agarwal A,

Kalantar-Zadeh K, Rankin LI, Singh H, Strassel L. (Eds). Inpatient Medical

Director Toolkit. Forum of ESRD Networks. 2020

8. Agarwal A, Henner D, Rankin L. Water systems for inpatient dialysis unit. In

Henner D, Agarwal A, Kalantar-Zadeh K, Rankin LI, Singh H, Strassel L. (Eds).

Inpatient Medical Director Toolkit. Forum of ESRD Networks. 2020

9. Agarwal AK. Access Care in the Covid era. Interventional Nephrology

Curriculum 2020. AVATAR, India.

10. Agarwal AK, Boubes, K, Haddad N. Chapter 3. Vascular Access for Home

Hemodialysis. In Lange: Handbook of Home Hemodialysis. Ed. Knicely D,

Abdel-Rahman E. McGraw Hill-Education. 2020.

11. Tan CS, Agarwal A, Wu S. Non-tunneled Hemodialysis Catheter. In Dialysis

Access Management, eds Kalva S and Wu S. Springer 2020.


1. Agarwal AK, Haddad NH. Management of AV access complications. In

Handbook of Interventional Nephrology. Eds. Vachharajani T and Jha V. Oxford

University Press, New Delhi, 2018.

2. Agarwal AK, Vachharajani T. High-output cardiac failure. In Handbook of

Interventional Nephrology. Eds. Vachharajani T and Jha V. Oxford University

Press, New Delhi, 2018.

3. Agarwal AK, Khabiri H, Haddad NJ. Central vein stenosis in hemodialysis:

Clinical presentation and intervention. In Innovations in Dialysis Vascular

Surgery. Ed. Chkhotua AB. Nova, NY, 2017.

4. Haddad NJ, Khabiri H, Agarwal AK, Asif A. Arteriovenous graft inflow stenosis.

Chapter in Dialysis Access Cases: Practical Solutions to Clinical Challenges.

Eds AS. Yevzlin, RR. Redfield III, Asif A, GA Beathard. Springer, 2016

5. Arteriovenous Vascular Access Monitoring and Complications. Yevzlin A,

Agarwal AK, Salman L, Asif A. In Handbook of Dialysis, Fifth Edition. Edited

by Daugirdas, Blake and Ing. Wolters Kluwer. 2015.

6. Tan CS, Wu S, Agarwal AK. Insertion of non-tunneled dialysis catheter. In

Hemodialysis Vascular Access Management, eds Kalva S and Wu S. Springer

2015.

7. Shah, R, Agarwal AK. Overview of Dialysis Arteriovenous Access. In

Ultrasound Approach to Chronic Kidney Disease and its Complications. Ed Di

Lullo L. OMICS Group eBooks. Foster City, CA. 2014.

8. Agarwal AK, Salman L. Common problems with vascular access: Overview

and Approach. In Handbook of Dialysis. Fifth Edition. Eds Daugirdas JT, Blake

P and Ing T. 2014.

9. Shah R and Agarwal AK. Approach to a Patient with Non- maturing AV Fistula.

In Interventional Nephrology: Principles and Practice. Eds Yevzlin A, Asif A,

Salman L. Springer, New York 2014.


10. Shah R and Agarwal AK. Approach to Arteriovenous Access. In Interventional

Nephrology: Principles and Practice. Eds Yevzlin A, Asif A, Salman L. Springer,

New York 2014.

11. Ash S, Narayan R, Agarwal A, Crabtree J. Operative considerations for

peritoneal dialysis catheter placement. In Interventional Nephrology: Principles

and Practice. Eds Yevzlin A, Asif A, Salman L. Springer, New York 2014.

12. Haddad NJ and Agarwal AK. Metabolic Acidosis and Alkalosis. Chapter in

Textbook of Nephrology. Edited by Mandal AK and Prakash J. Jaypee Brothers,

New Delhi, India. 2013.

13. Dhanireddy S and Agarwal AK. Cystic Diseases of the Kidney. Chapter in

Textbook of Nephrology. Edited by Mandal AK and Prakash J. Jaypee Brothers,

New Delhi, India. 2013.

14. Valentine C and Agarwal AK. Kidney Stones. Chapter in Textbook of

Nephrology. Edited by Mandal AK and Prakash J. Jaypee Brothers, New Delhi,

India. 2013.

15. Nori US and Agarwal AK. Assessment of Renal Function. Chapter in Textbook

of Nephrology. Edited by Mandal AK and Prakash J. Jaypee Brothers, New

Delhi, India. 2013.

16. Agarwal AK. Types of vascular access, characteristics and epidemiology. In

Interventional Nephrology. Eds Asif A, Agarwal A, Yevzlin A, Wu S, Beathard

G. McGraw Hill 2012.

17. Agarwal AK. Central vein stenosis. In Interventional Nephrology. Eds Asif A,

Agarwal A, Yevzlin A, Wu S, Beathard G. McGraw Hill 2012.

18. Packer J, Agarwal AK. Certification and accreditation in Interventional

Nephrology. In Interventional Nephrology. Eds Asif A, Agarwal A, Yevzlin A,

Wu S, Beathard G. McGraw Hill 2012.


19. Agarwal AK, Schon D. Establishing vascular access centers. In Interventional

Nephrology. Eds Asif A, Agarwal A, Yevzlin A, Wu S, Beathard G. McGraw Hill

2012.

20. Agarwal AK, Vachharajani T. Accessory veins. In Interventional Nephrology.

Eds Asif A, Agarwal A, Yevzlin A, Wu S, Beathard G. McGraw Hill 2012.

21. Ash S and Agarwal A. Definition of peritoneal catheter complications and

proper function. Core curriculum for peritoneal dialysis catheter procedures.

Peritoneal dialysis curriculum. American Society of Diagnostic and

Interventional Nephrology. 2011. Also online at

http://www.amazon.com/Curriculum-Peritoneal-Dialysis-Catheter-

Procedures/dp/1452893233/ref=sr_1_1?ie=UTF8&s=books&qid=1296141483

&sr=8-1

22. Ash S and Agarwal A. Peritoneal dialysis catheters designs and overview of

placement techniques. Core curriculum for peritoneal dialysis catheter

procedures. American Society of Diagnostic and Interventional Nephrology.

2011. Also online at http://www.amazon.com/Curriculum-Peritoneal-Dialysis-

Catheter-

Procedures/dp/1452893233/ref=sr_1_1?ie=UTF8&s=books&qid=1296141483

&sr=8-1

23. Agarwal AK. Hemodialysis Access. In Manual of Vascular Diseases. 2nd

Edition. Edited by Rajagopalan S, Mukherjee D, Mohler E. Lippincott Williams

and Wilkins. Philadelphia, USA, 2011.

24. Agarwal AK and SD Katz. Future Directions in management of anemia of heart

failure. In Heart Failure Clinics of North America. Edited by Agarwal AK, Singh

AK and Katz SD. Elsevier, 6: 385-395, 2010. New York.


25. Agarwal AK and AK Singh. ESA Therapy and Renal and Non-Renal Outcomes.

In: Heart Failure Clinics of North America. Edited by Agarwal AK, Singh AK and

Katz SD. Elsevier, 6: 323-332, 2010. New York.

26. Agarwal AK, N Haddad and LA Hebert. Progression of kidney disease:

Diagnosis and Management. In Evidence Based Nephrology. In Malony DA

and Craig J (Eds). Evidence-Based nephrology. Hoboken, John Wiley & Sons.

2008:311-12.

27. Agarwal AK. Cystic Disease of the Kidney. In Textbook of Nephrology for the

Asian Pacific Physicians. 2nd edition. Edited by A. Mandal and A.K. Agarwal,

New Delhi, Jaypee Brothers. 2004.

28. Agarwal AK. Urinary Stones. In Textbook of Nephrology for the Asian Pacific

Physicians. 2nd edition. Edited by A. Mandal and A.K. Agarwal, New Delhi,

Jaypee Brothers. 2004.

29. Spetie DN and Agarwal AK. Metabolic Acidosis. In Textbook of Nephrology for

the Asian Pacific Physicians. 2nd edition. Edited by A. Mandal and A.K.

Agarwal, New Delhi, Jaypee Brothers. 2004.

30. Spetie DN and Agarwal AK. Clinical Assessment of Renal Function. In

Textbook of Nephrology for the Asian Pacific Physicians. 2nd edition. Edited by

A. Mandal and A.K. Agarwal, New Delhi, Jaypee Brothers. 2004.

31. Spetie DN, Haller LU and Agarwal AK. Updates in Nephrology. In Clinics in

Podiatric Medicine and Surgery. WB Saunders. Vol19 (1), 43-64, 2002.

32. Agarwal A and John PG. Cystic Disease of the Kidney. In Nephrology in

Primary Care. Edited by A Mandal and NS Nahman, Baltimore, Williams and

Wilkins, 215-227, 1998.

33. Agarwal A and Al Haddad C. In Fellows’ Handbook. Edited by N.S. Nahman,

Columbus, Nephrology Division, The Ohio State University. 45-55,1996.


Editorial

1. Agarwal AK, Oza- Gajera, B. Dialysis Access: The Future is Already Here.

Advances in Chronic Kidney

Disease. National Kidney Foundation. Elsevier. 2020.

2. Agarwal AK. Anemia after ICU: More Questions Than Answers. Critical Care

Medicine, 2009: 37:2108-

2109.

Peer reviewed journal articles

1. Agarwal AK, Boubes KY, Haddad NF. Essentials of vascular access for home HD. Adv Chronic Kid Dis. 2021. In publication.

2. Agarwal AK, Sequeira, A, Oza-Gajera BP, Ramani K, Packer J, Litchfield T, Nations M, Lerma EV. Lessons learnt and future directions in managing dialysis access during the COVID 19 pandemic: Patient and provider experience in the United States. J Vasc Access 2021; 1-9. https://doi.org/10.1177/11297298211027014

3. Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney International Supplements (2021) 11, 46–58; https://doi.org/10.1016/j.kisu.2020.12.003

4. Kalantar-Zadeh K, Henner D, Atkinson R III, Molony D, Agarwal A, Rankin LI, Singh H, Kenney RJ, Diamond LH, Norris KC, on behalf of the Medical Advisory Council of the National Forum of ESRD Networks, Inpatient Dialysis Services: Nephrologist Leadership and Improving Quality and Safety, Am J Kidney Dis 2021. doi: https://doi.org/10.1053/j.ajkd.2021.03.011.

5. Agarwal AK. Interventional Nephrology: Evolution, Challenges, and Opportunities. Kidney News. 2020;12:11-12.


6. Drawz PE, Agarwal A, Dwyer J, et al. Concordance between Blood Pressure

in SPRINT and Routine Clinical Practice: Results from the SPRINT EHR

Ancillary Study. 2020.

7. Agarwal AK. Should buttonhole cannulation of arteriovenous fistulas be used?

COMMENTARY. Kidney360 first published on 14 April 2020

doi:10.34067/KID.0001682020

8. Wasse H, Alvarez AC, Brouwer-Maier D, Hull JE, Blamuthusamy S, Litchfield TF, Cooper RI, Rajan DK, Niyyar VD, Agarwal AK, Abreo K, Lok CE, Jennings WC. Patient Selection, education, and cannulation of percutaneous arteriovenous fistulae: An ASDIN White Paper. J Vasc Access. 2020; 21:810-817. PMID: 31782685. DOI: 10.1177/1129729819889793

9. Shah R, Haddad N, Tuazon P, Van Cleef, S, Agarwal A. Arteriovenous Graft

Length and its Impact on Access Flow and Graft Interventions. J Vasc Access.

2020. In publication.

10. Agarwal AK. A central venous catheter that cannot be dislodged easily by a

confused patient(Letter). Annals of Internal Medicine 2019;171:386.

11. Agarwal AK, Haddad N, Boubes K. Avoiding problems in tunneled dialysis

catheter placement. Semin Dial 2019;32:535-540..

https://doi.org/10.1111/sdi.12845

12. Agarwal AK, Yee J. Hepcidin. Advances in Chronic Kidney Disease. 2019;

26:298-305.

13. Vachharajani T, Agarwal AK, Asif A. Diagnosis and treatment of graft and stent

infections. Semin Dial. Submitted.

14. Agarwal A, Haddad N, Asif A, Vachharajani T. Innovations in vascular access

for hemodialysis. Kidney Int 2019; 95:1053-1063.

15. Vachharajani T, Agarwal AK, Asif A. Vascular access of last resort. Kidney

International, 2018.


16. Singh G, Agarwal AK, Prosek J, Jayadev MSK, Singh A. Can killers be saviors?

Lupus, 2017;903-908.

17. Agarwal AK, Khabiri H, Haddad NJ. Complications of vascular Access:

Superior Vena Cava

Syndrome. Imaging Teaching Case. Am J Kidney Dis 2017; 69:309-313.

18. Agarwal AK, Ash SR and Principal Investigators of the CentrosFlo trial.

Maintenance of blood flow rate on dialysis with self-centering CentrosFlo

catheter: A multicenter prospective study. Hemodialysis Int 2016; 20:501–509.

19. Agarwal AK. Endovascular Interventions for Central Vein Stenosis. Kidney

Research and Clinical Practice. 2016; 34:228-232.

20. SPRINT Research Group. Wright JT, Williamson JD, Whelton PK, Snyder JK,

Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel

PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK,

Ambrosius WT and Collaborators including Agarwal AK. A Randomized Trial

of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;

373:2103-2116.

21. Agarwal AK. Systemic effects of hemodialysis access. Adv Chr Kid Dis. 2015;

22:459-465.

22. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter, R,

including Agarwal AK, et al. Cinacalcet, fibroblast growth factor-23, and

cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl

therapy to lower cardiovascular events (EVOLVE) trial(Article)(Open Access).

Circulation 2015;132:27-39.

23. Agarwal AK, Thakkar A, Haddad N. Role of percutaneous balloon angioplasty.

Semin Dial 2015; 28:27–29.

24. Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA,

including Agarwal AK, et al. The effects of cinacalcet in older and younger


patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower

cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 2015;10:791-799.

25. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC,

Fine LJ, Goff DC, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM,

Rocco MV, Snyder JK, Willamson JD, Wright JT, Whelton PK, SPRINT Study

Research Group including Agarwal AK. The design and rationale of a

multicenter clinical trial comparing two strategies for control of systolic blood

pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials.

2014; 11:532-546.

26. Agarwal AK, Shah R, Haddad NJ. Access Blood Flow Testing. Semin Dial

2014;27: 595-598

27. Mehrotra R, Agarwal A, Bargman JM, Himmelfarb J, Johansen KL, Watnick S,

Work J, McBryde K, Flessner M, Kimmel PL. On behalf of the Kidney Research

National Dialogue (KRND). Dialysis Therapies: A National Dialogue. CJASN

2014; 9: (4) 812-814

28. Agarwal AK, Haddad NJ, Khabiri H. How should symptomatic central vein

stenosis be managed in hemodialysis patients? Semin Dial 2014; 27: 278-281.

29. Shah R, Haddad N, Vachharajani T, Asif A and Agarwal AK. Thrombocytopenia

in ESRD patients: Epidemiology, Mechanisms and Interventional Nephrology

Perspective. Semin Dial 2014; 27:537–648.

30. Shah R, Vachharajani TJ, Asif A, Agarwal A. Learning from images: Subclavian

or Internal Jugular Tunneled Dialysis Catheter: Can we divulge the location?

The Open Urology & Nephrology Journal, 2013, 6, 69-71.

31. Agarwal AK. In reply to 'The Other Side of the Central Vein Stenosis Story'".

Correspondence section. Am, J Kidney Dis. 2013.

32. Shah R, Vachharajani TJ, Agarwal AK. Aneurysmal Dilatation of Dialysis

Arteriovenous Access. The Open Urology & Nephrology Journal, 2013, 6, 1-5.


33. Agarwal AK. Central Vein Stenosis. American J Kidney Dis. 2013; 61:1001-

15.

34. Shah R, Agarwal A. Anemia associated with chronic heart failure: Current

Concepts. Clinical Interventions in Aging. 2013; 8:111-122.

35. Prosek J, Agarwal A, Parikh S. Cardiorenal Syndrome and the Role of

Ultrafiltration in Heart Failure. Curr Heart Fail Rep 2013; 10:81-88.

36. Macdougall IC, Provenzano R, Sharma A, Spinowitz BS, Schmidt RJ, Pergola

PE, Zabanbeth RI, Tong-Starksen S, Mayo MR, Tang H, Polu KR, Duliege AM,

Fishbane S, PEARL study Groups including Agarwal AK. Peginesatide for

anemia in patients with chronic kidney disease not receiving dialysis. N Engl J

Med. 2013; 368:320-332.

37. Fishbane S, Schiller B, Locatelli F, Covic AC, Provenzano R, Wiecek A, Levin

NW, Kaplan M, Macdougall IC, Francisco C, Mayo MR, Polu KR, Duliege AM,

Besarab A and EMERALD study groups including Agarwal AK. Peginesatide

in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368:307-

319.

38. Parikh S, Nagaraja H, Agarwal A, Samavedi S, Nori U, Von Visger J, Andreoni

K, Pesavento T, Singh N. Impact of Post-Kidney Transplant

Parathyroidectomy on Allograft Function. Clinical Transplantation 2012;

27:387-402.

39. McNeely J, Parikh S, Valentine, C, Haddad N, Shidham G, Rovin B, Hebert L,

Agarwal A. Bath Salts: A Newly Recognized Cause of Acute Kidney Injury.

Case Reports in Nephrology; International Journal of Clinical Reviews. 2012.

doi:10.1155/2012/560854

40. Shah R, Haddad N, Agarwal A. Seroma related to Prosthetic Arteriovenous

graft. The Open Urology and Nephrology Journal. 2012; 5:33-34.


41. Roy-Chaudhury P, Yevzlin A, Bonventre JV, Agarwal A, Almehmi A, Besarab

A, Dwyer A, Hentschel D, Kraus M, Maya I, Pflederer T, Schon D, Wu S, Work

J. Academic Interventional Nephrology: A Model for Training, Research, and

Patient Care. Clinical Journal of American Society of Nephrology. 2012; 7:521-

524.

42. Agarwal AK. Peritoneal Dialysis and Interventional Nephrology. Kidney News.

June 2012.

43. Singh N, Agarwal AK. The Clinical Picture: High creatinine 6 months after renal

transplant. Cleveland Clin J Med. 2012; 79:174-175.

44. Singh N, Agarwal AK. Pumping iron: revisiting risks, benefits and strategies in

treatment of iron deficiency in end-stage renal disease. Clinical Nephrology.

2012; 77:188-94

45. Haddad N, Winoto J, Shidham G, Agarwal AK. Hemodialysis access

monitoring and surveillance- how and why? Frontiers in Bioscience, E4, 2012;

2396-2401.

46. Shah R, Shidham G, Agarwal A, Albawardy A, Nadasdy T. Diagnostic utility of

kidney biopsy in patients with sarcoidosis and acute kidney injury. International

Journal of Nephrology and Renovascular Disease. 2011; 4:131-136.

47. Parikh S, Nijmeh R, Van Cleef S, Timmerman S, Bhatt UY and Agarwal AK,

Catheter Outcomes in the Short-term Inpatient Setting: A Controlled Quality

Improvement Study Comparing Citrate and Heparin Lock. Seminars in Dialysis,

2011; 25:351-356.

48. Shah R, Bhatt UY, Van Cleef S, Farley M, Davis A, Swope M, Agarwal AK.

Vascular Access Thrombosis and Interventions in Patients Missing

Hemodialysis Sessions. Clinical Nephrology. 2011; 76:435-439.

49. Agarwal AK. Pros and Cons of Interventional Nephrology. Renal & Urology

News. 2010; 9: 34-36.


50. Haddad NH, Vachharajani T, Van Cleef S, Agarwal AK. Iatrogenic graft to vein

fistula (GVF) formation associated with synthetic arteriovenous grafts. Semin

Dial 2010; 23:643-647.

51. Vachharajani TJ, Moossavi S, Salman L, Wu S, Maya ID, Yevzlin AS, Agarwal

A, Abreo KD, Work J, Asif A. Successful Models of Interventional Nephrology

at Academic Medical Centers. Clin J Am Soc Nephrol 2010; 5:2130-2136.

52. Nori US, Agarwal AK, Von Visger JR. Dietary therapy in hypertension.

Correspondence. N Engl J Med 2010; 363:1580-1581.

53. Asif A, Salman L, Carrillo RG, Garisto JD, Lopera G, Barakat U, Lenz O,

Yevzlin A, Agarwal A, Gadalean F, Sachdeva B, Vachharajani TJ, Wu S, Maya

ID, Abreo K: Patency rates for angioplasty in the treatment of pacemaker-

induced central venous stenosis in hemodialysis patients: results of a multi-

center study. Semin Dial 2009; 22:671–676.

54. Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A,

Kewalramani R. Every-other-week darbepoetin alfa in the correction and

maintenance of haemoglobin levels in elderly patients with chronic kidney

disease: post hoc subanalysis of data from two clinical trials. Drugs Aging. 2009;

26:665-75.

55. Agarwal A. Central vein stenosis: Current concepts. Advances in Chronic

Kidney Disease 2009;16: 360-370.

56. Horowitz J, Agarwal A, Huang F, Gitlin M, Cangialose C. Population-level

Erythropoiesis-Stimulating Agent dose conversion ratio in chronic kidney

disease. J Managed Care Pharm, 2009;15:741-750.

57. Agarwal AK. Drug Safety Profile of Darbepoetin Alfa for anemia of chronic

kidney disease. Expert Opinion on Drug Safety 2009; 8:145-153.

58. Agarwal AK. Expert review of Clinical Pharmacology: Darbepoetin Alfa. Expert

Rev Clin Pharmacol 2008; 1:369-379.


59. Nori US, Agarwal AK, Rovin BH. Letter to the Editor. Original Article-

Teriparatide or Alendronate in glucocorticoid-induced osteoporosis. N Engl J

Med 2008; 358:1302-1303.

60. Budu-Grajdeanu P, Schugart RC, Friedman A, Valentine C, Agarwal AK,

Rovin BH. A mathematical model of venous neointimal hyperplasia formation.

Theoretical Biology and Medical Modeling 2008; 5:1-9.

61. Silver M, Agarwal A, Krause M, et al. Effect of Darbepoetin Alfa administered

once monthly on maintaining hemoglobin levels in older patients with chronic

kidney disease. The American Journal of Geriatric Pharmacotherapy 2008;

6:49-60.

62. Agarwal AK. Early Treatment of Anemia in CKD: To Treat Or Not To Treat.

US Renal Disease 2007; 47-52.

63. Haddad N, Rajan J, Nagaraja HN, Agarwal AK, Hebert LA. Usual ACE inhibitor

therapy in CKD patients is associated with lower plasma aldosterone levels

than usual ARB therapy. Kidney and Blood Pressure Research 2007; 30:299-

305.

64. C Brown, N Haddad, A Agarwal. An unexpected finding during tunneled

dialysis catheter exchange. Nephrology Image. Kidney International 2007;

71:599.

65. Agarwal AK, Patel BM and Haddad NJ. Central vein stenosis: A nephrologist’s

perspective. Seminars in Dialysis 2007; 20:53-62.

66. Agarwal AK, Silver MR, Walczyk M, et al. Once-monthly Darbepoetin alfa for

Maintaining Hemoglobin Levels in Older Patients With Chronic Kidney Disease.

J Am Dir Assoc 2007; 8:83-90.

67. Agarwal AK. Practical Approach to the Diagnosis and Treatment of Anemia

Associated With CKD in Elderly. J Am Med Dir Assoc 2006; 7:s7-s12.


68. Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin

alfa administered once monthly for the maintenance of haemoglobin

concentrations in patients with chronic kidney disease not receiving dialysis. J

Int Med 2006; 260:577-585. (IP 4.040)

69. Spetie D, Nadasdy T, Nadasdy G, et al, including Agarwal A: Proposed

pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kid Dis 2006;

47(3):419-427. (IP 4.412)

70. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R: Darbepoetin alfa

administered once monthly maintains hemoglobin concentrations in patients

with chronic kidney disease. Clinical Nephrology, 2005; 63:327-334.

71. Lindberg J, Culleton B, Wong G, et al, including Agarwal A. On behalf of

Cinacalcet Hcl 20000188 study group: Cinacalcet HCL, an oral calcimimetic

agent for the treatment of secondary hyperparathyroidism in hemodialysis and

peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc

Nephrol 2005;16: 800-807.

72. Hebert LA, Rovin BH, Agarwal AK, Spetie DN. Cyclophosphamide or

chlorambucil therapy is indicated in idiopathic membranous nephropathy with

strong risk factors for progression. Letter to Editor. Am J Kidney Dis 2005;45:

788-789.

73. Asif A, Pflederer T, Vieira C, Diego J, Roth D, Agarwal A: Does catheter

insertion by Nephrologists improve peritoneal dialysis utilization? A multicenter

analysis. Seminars in Dialysis 2005; 18:157-160.

74. Toto RD, Pichette V, Navarro J, Liu W, Brenner R, Carroll W, Simon R. On

behalf of Aranesp 990788 Study Group: Darbepoetin alfa effectively treats

anemia in patients with chronic kidney disease with de novo every other week

administration. Am J Nephrol. 2004; 24:453-460.


75. Agarwal AK and Ross, JR: A-V graft salvage after trauma. Endovascular

Today. 2004; 3:16-17.

76. Agarwal AK, Wilmer WA, Bay WH, Falkenhain ME, Mangino JE:

Pneumococcal and gonococcal peritonitis due to vaginitis. Letter to Editor.

Peritoneal Dialysis International. 2002; 22:731-732.

77. Agarwal A, Clements J, Sedmak DD, Imler D, Nahman NS Jr., Orsinelli DA,

Hebert LA: Subacute Bacterial Endocarditis masquerading as type III essential

mixed cryoglobulinemia. J Am Soc Nephrol 1997; 8:1971-1976.

78. Cosio FG, Roche Z, Agarwal A, Falkenhain ME, Sedmak DD, Ferguson RM:

Prevalence of Hepatitis C in patients with idiopathic glomerulopathies in native

and transplant kidneys. Am J Kid Dis 1996; 28:752-758.

79. Hebert LA, Agarwal G, Ladson-Wofford SE, Hiremath L, Carlton SG, Nahman

NS, Jr, Falkenhain ME, Agarwal A: Nocturnal blood pressure in treated

hypertensive African- Americans compared to treated hypertensive European-

Americans. J Am Soc Nephrol 1996; 7:2130-2134.

80. Shukla GD, Mishra DN, Agarwal AK: Non- organic Dyspepsia: A controlled

clinicopsychiatric study. J Asso Phys India 1984; 32:399-402.

81. Shukla GD, Mishra DN, Agarwal AK: Non-organic Dyspepsia: A controlled

psychometric study. Indian J Psych 1982; 24:280-283.

PUBLISHED ABSTRACTS AND PRESENTATIONS 1. Boubes K, Haddad N, Agarwal A. AA Novel Method for Ligation of Accessory

Veins: A Case Series of Eight Patients. PO 1034. American Society of Nephrology 2022.

2. Metwally S, Boubes K, Agarwal AK. A tale of two accesses: The enemy of good is better. Abstract number: WCN22-0354. World Congress of Nephrology, Kualalampur, 2022.


3. Agarwal AK, Roy Chaudhury P, Allon M, Chew P, Masson E, Poggio E, Pfaffle

A. LOCK-IT-100: CRMD003, A novel taurolidine-based catheter lock solution

reduces catheter related bloodstream infections in hemodialysis. Late breaking

session Oral Presentation. National Kidney Foundation Spring Clinical Meeting,

Boston. 2019.

4. Shah R, Haddad N, Boobes, K, Van Cleef S, Agarwal AK. Timing and

Appropriate Type of Dialysis Vascular Access Creation Remains A Mystery.

Korean Society of Interventional Nephrology meeting. Seoul, S Korea. 2019.

5. Shah R, Haddad N, Boobes, K, Van Cleef S, Agarwal AK. Timing and

Appropriate Type of Dialysis Vascular Access Creation Remains A Mystery.

American Society of Diagnostic and Interventional Nephrology meeting. Atlanta,

2019.

6. Outcomes of Coordinated Vascular Access Placement. Shah R, Haddad N,

Boobes K, Van Cleef S, Agarwal AK. American Society of Nephrology Annual

Meeting. San Diego. 2018.

7. Shah R, Haddad N, Tuazon P, Van Cleef S, Agarwal AK. Arteriovenous Graft

Length and its Impact on Access Flow and Graft Interventions. American

Society of Diagnostic and Interventional Nephrology. Oral presentation. Salt

Lake City. 2018.

8. Bucktowarsing B, Shah R, Farah FR, Haddad NJ, Agarwal AK. An unusual

case of Steptococcus Vestibularis in a hemodialysis patient. National Kidney

Foundation Spring Clinical meeting, Austin, Florida 2017.

9. Bucktowarsing, B, Van Cleef, S, Shah, R, Haddad, N, Agarwal A.

Arteriovenous fistula causing high output cardiac failure with pulmonary

hypertension. American Society of Diagnostic and Interventional Nephrology

meeting. Salt Lake City, Utah. 2017.

10. Obabko A, Tsyrulnikov E, Rainsberger R, Torreira A, Nagib H, Agarwal A,


Fischer PF. Large Eddy Simulation of flows through a novel vascular access

device for hemodialysis access. American Society of Physics 70th meeting.

Denver. 2017.

11. Tsyrulnykov E, Agarwal A, Obako A. Vascular access device for hemodialysis

access. ASN Annual Meeting 2017.

12. Katout M, Haddad N, Van Cleef S, Agarwal A. Impact of hybrid graft catheter

access on hospitalizations, infections, and interventions in hemodialysis

patients with severe central vein stenosis. J Vasc Access, 2017. The Ohio State

University Wexner Medical Center, Columbus, OH, USA.

13. Sellers A, Agarwal A, Pryor L, Butler K, Maddux D, Maddux F. Use of a

handheld ultrasound device to support permanent hemodialysis vascular

access cannulation. J Vasc Access 2017. Fresenius Kidney Care OSU

Campus, Columbus, OH, USA and The Ohio State University Wexner Medical

Center, Columbus, OH, USA

14. Brod H, Binkley P, Agarwal A. Clinical Excellence: A Faculty Promotion

Pathway for the ACA Era. Group on Faculty Affairs Professional Development

Conference, AAMC, Boston. 2014.

15. West AM, Haddad N, Shah R, Van Cleef S, Agarwal A, Khabiri H.

Recanalization of upper extremity central vein occlusion to establish

Arteriovenous access in patients consigned to femoral catheters: A targeted

multidisciplinary approach. ASDIN, 2014.

16. Kayi P, Van Cleef S, Shah R, Agarwal A. Routine Pre-Procedural Labs for

Outpatient Interventional Nephrology procedures- Utility and Impact. ASDIN

2013.

17. Provenzano R, Hulter H, Agarwal A, Klaus S, Lee T, Yu P, Neff T. Hypoxia-

inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb

without Fe depletion in the absence of IV Fe. National Kidney Foundation


Spring Clinical Meeting, 2013.

18. McNeely J, Parikh S, Valentine, C, Haddad N, Shidham G, Rovin B, Hebert L,

Agarwal A. The spectrum of acute kidney injury in bath salts intoxication.

American Society of Nephrology. San Diego, 2012.

19. Nori US, Shah R, Haddad NJ, Agarwal AK. CKD care for patients with failing

kidney transplantation. American Society of Nephrology 2011.

20. Provenzano R, Hulter H, Agarwal A, Klaus S, Lee T, Yu P, Neff T. Hypoxia-

Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI) Corrects Anemia

without Fe Depletion in the Absence of IV Fe. ASN 2011.

21. Kayi P, Kamadana S, Agarwal A. Acute kidney injury as the initial presentation

of acute retroviral syndrom. Poster Presentation. National Kidney Foundation

Spring Clinical Meeting, 2011

22. Parkih SV, Samavedi S, Singh N, Agarwal AK. Impact of post kidney transplant

parathyroidectomy on early graft function. Poster presentation. American

Society of Nephrology. Denver, 2010

23. Shah R, Agarwal A, Sahani L, Sreedhar R. Use of HMG-CoA reductase

inhibitors and incidence of acute kidney injury in critically ill patients with sepsis.

Poster presentation. American Society of Nephrology. Denver, 2010

24. Parikh SV, Barnes CE, Bhatt UY, Van Cleef S, Haddad NJ, Agarwal AK. The

viability of arteriovenous access for hemodialysis in elderly versus middle-aged

patients. Poster presentation. American Society of Nephrology. Denver, 2010

25. Parikh SV, Njmeh R, Bhatt U, Agarwal AK. Acid Citrate Dextrose Vs. Heparin

locks: Comparing catheter outcomes for short term inpatient hemodialysis.

Midwest Fellows Research Conference. Oral presentation. Chicago, 2010

26. Shah R, Van Cleef, S, Bhatt U, Davis A, Ross M, Swope M, Agarwal A. impact

of missing hemodialysis sessions on arteriovenous access thrombosis.

Midwest Fellows Research Conference. Oral presentation. Chicago, 2010.


27. Burnett TM, Moore J, Agarwal AK. Tick, tack, ohhh...when a mole is actually a

tick. An unusual cause of bacteremia. American College of Physicians, Annual

meeting. Submitted 2010.

28. Shah R, Van Cleef, S, Bhatt U, Davis A, Ross M, Swope M, Agarwal A. impact

of missing hemodialysis sessions on arteriovenous access thrombosis.

American Society of Diagnostic and Interventional Society annual meeting,

2010.

29. Nijmeh R, Parikh S, Timmerman S, Bhatt U, Agarwal A. Citrate Vs Heparin

lock: Comparing catheter outcomes for short-term inpatient hemodialysis. NKF

Spring Clinical Meeting, 2010.

30. Samavedi S, Parikh S, Gunay Y, Agarwal A, Von Visger J, Nori U, Pesavento

T, Henry M, Singh N. Impact Of Post Kidney Transplant Parathyroidectomy On

Early Graft Function. NKF Spring Clinical Meeting, 2010.

31. Kharat V, Van Cleef S, Hiremath L, Haddad N, Brown C, Agarwal A. Does Vein

Mapping Change Access Placement Rates? The Ohio State University Medical

Center Research Day 2009.

32. Agarwal A, Kewalramani R, Droge J, Huang F, McClellan W. Hemoglobin

variability in subjects with chronic kidney disease not receiving dialysis: An

analysis of Darbepoetin Alfa clinical trial data. Am J Kid Dis 2009; A23.

33. Haykal MK, Abdelhadi NA, Rahman MA, Agarwal A, Nkruma M, Ahmed S,

Mohammad YM. The Migraine- Blood Pressure Connection: Solving the Puzzle.

61st annual meeting of American Academy of Neurology. 2009.

34. Brenner L, Bolton WK, Agarwal A, Bender J, Coyne D. Theoretical Safety

Concerns with Anemia Therapies: Results Following Ferumoxytol and Oral Iron

Treatment in CKD Patients. J Am Soc Nephrol 2008. J Am Soc Nephrol 2008;

19:730A.

35. Kharat V, Van Cleef S, Hiremath L, Haddad N, Brown C, Agarwal A. Does Vein


Mapping Change Access Placement Rates? J Am Soc Nephrol 2008; 19:259A.

36. Agarwal A, Horowitz J, Phelan M, Cangialose C, and Audhya P. Analysis of

the dose relationship between recombinant human erythropoietin and

darbepoetin alfa in elderly patients with chronic kidney disease not on dialysis.

ASCP annual meeting 2008. Poster Presentation.

37. Horowitz J, Agarwal A, Phelan M and Audhya P. Analysis of the dose

relationship between Epoetin alfa and Darbepoetin alfa in patients with chronic

kidney disease not on dialysis. AMCP annual meeting 2008. Poster

Presentation.

38. Zakaria S, Habib P, Valentine C, Shidham G, Agarwal A. An unusual cause of

malignant hypertension. Am J Kidney Dis 2008; 51:B84.

39. Waheed M, Brown C, Haddad N, Van Cleef S, Bhatt U, Agarwal A. Central

venous stenosis in Systemic Lupus Erythematous Associated ESRD. American

Society of Diagnostic and Interventional Society annual meeting, 2008. Poster

Presentation.

40. Parikh SV, Brown CG, Haddad N, et al including Agarwal A. Prevalence of

Central Venous Stenosis with Internal Jugular Dialysis Catheters in End Stage

Renal Disease Patients. J Am Soc Nephrol 2007; 18:268A.

41. Kashyap R, Waheed U, Brown C, et al including Agarwal A. Pacemaker

Associated Central Venous Stenosis in Hemodialysis Patients: Incidence and

Outcomes. J Am Soc Nephrol 2007; 18:267A.

42. Agarwal A, De novo every−other−week (Q2W) Darbepoetin Alfa treatment

corrects and maintains hemoglobin levels in patients with chronic kidney

disease. J Am Soc Nephrol 2007; 18:758A.

43. Agarwal A, The Effect of Baseline Estimated Glomerular Filtration Rate

(eGFR) on Hemoglobin (Hb) Response within the first 12 Weeks after

Converting to Once−Monthly (QM) Darbepoetin Alfa Treatment in Patients with


Chronic Kidney Disease. Poster Presentation. American Society of Nephrology

annual meeting, 2007.

44. Mandal A, Patnaik A, Agarwal A, Nagaraja A. Effect of antihypertensive

therapy on renal function in Asian Indian Diabetic patients. J Am Soc Nephrol

2007; 18:847A.

45. Shidham G, Van Cleef S, Agarwal A. Is Online Access Flow Measurement as

Accurate as Doppler Flow in Predicting Need for Access Intervention in Dialysis

Patients? Oral Presentation. Annual meeting of North American Society for

Hemodialysis and Transplantation, Hawaii, 2007.

46. Krause M, Raja R, Agarwal A, et al. De novo Darbepoetin alfa Administered

Every Other Week (Q2W) Corrects and Maintains Hemoglobin (Hb) Levels in

Older Patients With Chronic Kidney Disease. Poster Presentation. American

Society of Consultant Pharmacists, 2007.

47. Krause M, Agarwal A, Silver M, et al. De novo every other week (Q2W)

Darbepoetin alfa used to correct hemoglobin levels in older chronic kidney

disease subjects naïve to erythropoiesis stimulating protein treatment. Poster

Presentation. American Geriatric Society, 2007.

48. Agarwal A, Chen C, Klassen P, Kewalramani R. Effect of baseline estimated

glomerular filtration rate on the efficacy of once-monthly Darbepoetin alfa in the

maintenance of hemoglobin levels in patients with chronic kidney disease.

Poster presentation. National Kidney Foundation annual meeting, 2007. Am J

Kid Dis 2007; A25.

49. Haddad N, Brown C, Van Cleef S, Agarwal A. Iatrogenic fistula formation

between Arteriovenous graft and adjacent vein. Poster Presentation. The

American Society of Diagnostic and Interventional Nephrology annual meeting.

2007.

50. Parikh S, Brown C, Van Cleef S, Haddad N, Agarwal A. Internal Jugular


dialysis catheters are associated with high incidence of central vein stenosis in

end stage renal disease patients. Poster Presentation. The American Society

of Diagnostic and Interventional Nephrology annual meeting. 2007.

51. Parikh S, Brown C, Van Cleef S, Haddad N, Agarwal A. Internal Jugular

dialysis catheters are associated with high incidence of central vein stenosis in

end stage renal disease patients. Poster Presentation. Graduate and Post

Graduate research day. The Ohio State University. 2007.

52. Mandal AK, Patnaik A, Agarwal AK, Nagaraja HN. Effect of blood glucose and

blood pressure control on renal function in Asian Indian diabetic patients with

chronic kidney disease. International Society of Nephrology meeting 2007.

53. Nadasdy T, Nadasdy G, Agarwal G, et al, including Agarwal A. Idiopathic thick

basement membrane nephropathy: A newly recognized cause of glomerular

hematuria. J Am Soc Nephrol, 17: 258A, 2006.

54. Agarwal AK, Patnaik A, Mandal AK, Nagaraja HN. Cross Sectional

Measurements of Blood Glucose and Blood Pressure Correlate Highly with

Outcomes in Diabetic Asian Indian Patients. J Am Soc Nephrol, 17: 909A, 2006.

55. Silver MR, Krause M, Agarwal A, et al. Once-Monthly (QM) Aranesp®

(Darbepoetin alfa) Maintains Target Hemoglobin (Hb) Levels in Older Patients

With Chronic Kidney Disease (CKD). Poster presentation at Am Soc Consultant

Pharmacists meeting, 2006.

56. Silver MR, Agarwal A, Lei L, et al. Once-Monthly (QM) Aranesp® (Darbepoetin

alfa) Maintains Hemoglobin (Hb) Levels in elderly patients with Chronic Kidney

Disease (CKD). Poster presentation at Academy of Managed Care Pharmacy

meeting, 2006.

57. Agarwal A, Krause M, Silver MR, et al. Once-monthly (QM) Darbepoetin alfa

effectively maintains hemoglobin levels in older patients with chronic kidney

disease. Poster presentation, Am Geriatric Soc meeting, 2006.


58. Brown C, Agarwal A, Valentine C. Retropharyngeal abscess: A rare

complication of line related bacteremia in a patient with ESRD. Poster

presentation at The Ohio State University Graduate and Postgraduate

Research Day, 2006.

59. Agarwal A, Krause M, Silver M, Liu W, Audhya P. Once-monthly (QM)

Darbepoetin alfa effectively maintains hemoglobin levels in older patients with

chronic kidney disease. Poster presentation, American Geriatric Society

meeting, 2006.

60. Agarwal AK, Agarwal G, Seth S, Hartman J, Spetie D, Hebert LA. Chronic

daily intravenous Sodium Thiosulphate therapy does not consistently alter pain

or narcotic use in loin pain hematuria syndrome (LPHS). J Am Soc Nephrol, 16:

781A, 2005.

61. Farhan N, Rajan J, Agarwal A, Hebert L. ACE Inhibitors suppress plasma

aldosterone better than Angiotensin Receptor Blockers in chronic kidney

disease. J Am Soc Nephrol, 16: 616A, 2005.

62. Biyyani RS, Burdge K and Agarwal AK. Bisphosphonate therapy: A rare cause

of hyperphosphatemia. Abstract, J Am Soc Nephrol, 16: 906A, 2005.

63. Silver MR, Agarwal AK, Walczyk MH, Fadda G, Varma N, Liu W, Stehman-

Breen, C. De novo every-other-week (Q2W) Aranesp (Darbepoetin Alfa) dosing

in patients with chronic kidney disease (CKD) not receiving dialysis. J Am Soc

Nephrol, 16: 762A, 2005.

64. Hertel J, Locay H, Scarlata D et al including Agarwal A as part of the STAAR

Study Group. Every-other-week Aranesp (Darbepoetin Alfa) achieves and

maintains target hemoglobin levels and improves health-related quality of life

in recombinant human erythropoietin naïve patients with chronic kidney

disease. J Am Soc Nephrol, 16: 2005.


65. Ling B, Walczyk M, Agarwal A, Carroll W, Scarlata D, Brenner R. Darbepoetin

alfa administered once monthly maintains hemoglobin in CKD patients. Poster

presentation at AMDA Annual meeting. New Orleans. 2005.

66. Hertel J, Locay H, Scarlata D, et al including Agarwal A. On behalf of the

STAAR study group Darbepoetin Alfa administered every other week (Q2W)

corrects and maintains hemoglobin in chronic kidney disease patients. Poster

presentation at the NKF meeting. 2005.

67. Agarwal AK, Patel BM, Farhan NJ: Central venous stenosis in hemodialysis

patients is a common complication of ipsilateral central vein catheterization. J

Am Soc Nephrol,15:368A, 2004.

68. Agarwal AK, Spetie D: Declining utilization of peritoneal dialysis in a large

academic clinical nephrology program. J Am Soc Nephrol, 15:.811A, 2004.

69. Mittman N, Finkelstein F, Culleton B, Charytan C, Agarwal A, Albizem MA,

Guo MG, Klassen PS, Sprague SM: Cinacalcet HCl (Sensipar) for the

management of secondary hyperparathyroidism (HPT) in patients receiving

peritoneal dialysis (PD). J Am Soc Nephrol, 15:280A, 2004.

70. Hebert LA, Nadasdy T, Agarwal G, Mauer M, Agarwal AK, Nadasdy G, Spetie

DN, Nahman NS. Proposed diagnostic criteria and classification of Loin Pain

Hematuria Syndrome (LPHS) based on kidney biopsy in 83 patients. J Am Soc

Nephrol, 15:117A. 2004.

71. Agarwal A, Ling B, Walczyk M, Carroll W, Liu W, Brenner R: Aranesp

(Darbepoetin Alfa) administered once monthly maintains hemoglobin levels in

patients with chronic kidney disease (CKD). Poster presentation, European

Renal Association-European Dialysis and Transplantation Association meeting,

Lisbon. 2004.


72. Agarwal A, Ling B, Walczyk M, Carroll W, Liu W, Brenner R: Aranesp


patients with chronic kidney disease (CKD). Am J Kid Dis. A15, 2004.

73. Walczyk M, Agarwal A, Ling B, Carroll W, Liu W, Brenner R: Aranesp


patients with chronic kidney disease. J Am Soc Nephrol, 14:770A, 2003.

74. Agra A, Agarwal AK: Hemodialysis as an alternative to Charcoal

Hemoperfusion for treatment of acute Carbamazepine toxicity. J Am Soc

Nephrol, 14:817A. 2003.

75. Ayran MD, Wilmer WA, Falkenhain ME, Agarwal AK, Magro CA: Painless

ischemic myopathy of calciphylaxis. J Am Soc Nephrol, 14:787A. 2003.

76. Agarwal AK, Agarwal G, VanCleef SS, Cosio FG: Shunt survival in

hemodialysis patients depends upon cardiac function. J Am Soc Nephrol,

11:179A. 2000.

77. Agarwal AK, Bay WH, Cosio FG, VanCleef SS, Hebert LA: Seasonal variation

in incidence of infection in long term tunneled catheters (LTTC) and Gore-Tex

grafts (GG) used as hemodialysis vascular access (HVA). J Am Soc Nephrol,

10:200A. 1999.

78. Agarwal AK, Ladson-Wofford SE, Middendorf DM, Bay WH, Hebert LA:

Declining incidence of spinal epidural abscess in a large chronic hemodialysis

program. J Am Soc Nephrol: 9:241A. Poster presentation at ASN meeting,

Philadelphia, Pa. 1998.

79. Agarwal AK, Agarwal G, Bay WH, Middendorf DM, Ladson-Wofford SE,

Fromkes J, Sundaram U, Hebert LA: Unexplained nausea in ESRD patients is

usually a manifestation of acid peptic disease. J Am Soc Nephrol, 9:241A, 1998.


80. Agarwal AK, Thomas AJ: Male infertility in autosomal dominant polycystic

kidney disease due to ductal obstruction from dilatation of seminal vesicles. J

Am Soc Nephrol, 9:370A, 1998.

81. Ladson-Wofford SE, Agarwal G, Agarwal A, Reif M, Hebert LA: Relationship

between socioeconomic status and nocturnal blood pressure in treated

hypertensive African-Americans compared to treated hypertensive European-

Americans. J Am Soc Nephrol,7:1552A, 1996.

82. Agarwal A, Cosio FG, Roche Z, Falkenhain ME, Ferguson RM: Prevalence of

Hepatitis C antibodies in patients with glomerulonephritis of native and

transplant kidneys. J Am Soc Nephrol, 6:410A, 1995.

Research Thesis

A Clinico-psychiatric Study of Patients with Non-organic Dyspepsia. 1981-82.

Editor reviewed journal articles 1. Agarwal AK, Lerma EV. Editors. Interventional Nephrology issue. Kidney

News, September 2020. American Society of Nephrology. https://www.kidneynews.org/kidney-news/issues/september-2020-(vol.-12,-number-9)

2. Agarwal A. Managing cardiovascular risk: Special considerations in patients

with chronic kidney disease. Case presentation. Advanced Studies in Medicine,

Johns Hopkins University Press. July 2005.

Online Peer Reviewed Articles/CME

1. Agarwal AK. NephMadness20 commentary on percutaneous arteriovenous

fistula creation.

https://ajkdblog.org/2020/04/16/nephmadness-2020-percutaneous-avf-


creation-will-revolutionize-care-in-hemodialysis/

2. Hentschel D, Agarwal AK, Lawson J. Maintaining Lifelines for ESKD patients:

ASDIN-VASA joint statement for Covid 10 restrictions on procedures. March

2020.

https://www.asdin.org/news/496853/ASDIN-and-VASA-Issue-Joint-Statement-

--Maintaining-Lifelines-for-ESKD-Patients.htm accessed 4.18.2020.

3. Agarwal AK. National Kidney Foundation Spring Clinical Meeting 2019

enduring CME titled Anemia in CKD: Arming Clinicians with Meaningful

Solutions. https://education.kidney.org/content/anemia-chronic-kidney-

disease-arming-clinicians-meaningful-solutions#group-tabs-node-course-

default4

4. Agarwal AK, Szczech L, Wish J. Anemia in CKD. Hemoglobin Variability:

Individualization of Anemia Management for the Patient with End Stage Renal

Disease. Online CME. National Kidney Foundation 2013.

www.kidney.org/cme.

5. Wish J, Covesdy C, Agarwal A. Anemia in CKD Stage 5: Balancing Morbidity,

Mortality, and Quality of Life. Online CME. National Kidney Foundation 2012.

www.kidney.org/cme.

6. Agarwal AK. Extended dosing of erythropoietin for treatment of anemia of

kidney disease.

Medscape Nephrology 2005;7(1).

http://www.medscape.com/viewarticle/501936.

Online and media coverage

1. Agarwal AK. Hot Topics in Nephrology. Mechanisms and role of PHI in chronic kidney disease and anemia. Kidney Colloquium Podcast. 2021.


Twitter. 2. Agarwal AK. Visualizing the potential role of HIF-PH inhibitors in the

treatment of anemia in chronic kidney disease. 2021. Peer view. https://learn2.peerview.com/150206303/150206303_p1/specialty?Promocode=&CountryID=US&ProjectNumber=150206303

3. Agarwal AK. Dialysis Vascular Access Related Emergencies - Clinical Case Discussion. 2021. Enduring activity based on National Kidney Foundation SCM21 presentation.

4. Agarwal AK. Continuous renal replacement therapy and circuit failure.

Webcast, Reach MD. June 2020. https://reachmd.com/profiles/anil-agarwal-

md/L23v1d/

5. Agarwal AK, and Boubes K. ASN Kidney 360 podcast. Debate in Nephrology

entitled, “Should buttonhole cannulation of arteriovenous fistulas be used?”

June 2020. https://bit.ly/KPOD0001682020.

6. Agarwal AK. NephMadness 2020 Commentary on Percutaneous AV Fistula.

https://ajkdblog.org/2020/04/16/nephmadness-2020-percutaneous-avf-

creation-will-revolutionize-care-in-hemodialysis/ Accessed June 7, 2020.

7. Agarwal AK, Ashfaq N, Metwally S. Ohio State Nephrologists Enhance

Kidney Disease Management with Point-of-Care Ultrasound. Featured

Facebook release by OSUWMC. March 2020.

https://wexnermedical.osu.edu/departments/innovations/nephrology/point-

care-ultrasound/?utm_source=facebook&utm_medium=paid-

social&utm_campaign=med_general-

engagement_fy20&fbclid=IwAR15of4WfTtxPp0fCcPj3a4u08qgtzztvgeOrtJbY

nZaX8mmioKQVt9QKh4

8. Agarwal AK. 42 Signs Your Kidneys Are in Big Trouble. Reader’s Digest, May

2015

a. Online audience: 3.5 million


b. More than 26 million Americans suffer from kidney disease—from

kidney stones to infections to cancer. Learn the signs that your

kidneys are in big trouble with this expert-approved guide. Dr. Anil

Agarwal is quoted.

9. Agarwal AK. Neutrolin Cuts Catheter-Based Blood Infection Risk in

Hemodialysis

a. MedPage Today, May 2015; Online audience: 1.5 million

b. Medical Health News, May 2015; Online audience: 10,013, May11,

2019

c. An investigational catheter lock solution significantly decreased

catheter-related bloodstream infections among end-stage renal

disease patients with hemodialysis through a central venous catheter,

according to researchers here. Dr. Anil Agarwal is quoted.

10. Agarwal AK. Webinar on ‘Central Vein Stenosis. International Society of

Nephrology. 2013.

11. Agarwal AK. Nephrogenic Fibrosing Dermopathy. News item on 10 TV

Columbus, Ohio, 2010.

12. Agarwal AK. Dialysis and transplantation. News item on NBC4, Columbus,

Ohio, 2010.

13. Agarwal AK. Once monthly de novo Darbepoetin alfa may be effective in

anemia of CKD. April, 2007. http://www.medscape.com/viewarticle/555839.

14. Agarwal AK. Trends in Medicine: Computer Assisted Anemia Management.

2007.

15. Agarwal AK. Renal and Urology News: Monthly Darbepoetin still safe, effective.

P.1. Jan 2006.

16. Agarwal AK. Video news Release: Reduced complications, costs drive fistula

use. OSU. October 2005.


17. Agarwal AK. Doctor’s Guide: NKF: Darbepoetin alfa effective with once-

monthly dosing. www.docguide.com/dg.nsf. 2004.

18. Agarwal AK. Doctor’s Guide: ASN: Once-monthly Darbepoetin alfa protects

patients with chronic kidney disease from anemia.www.docguide.com/news,

2003.

PRESENTATIONS:

International: 1. Chair. Session on Endovascular Intervention. April 15.2021. World Congress

of Nephrology. International Society of Nephrology. Vancouver (virtual). 2. Endovascular Techniques for Thoracic Central Vein complete Occlusion.

Session: Fundamental course 3. Vascular Access Society 2021 Congress. April 8, 2021 (Berlin- Virtual).

3. Prevention of infection of CVC. Session: Fundamental course 3. Vascular Access Society 2021 Congress. April 8, 2021 (Berlin- Virtual).

4. Anemia and ESA in Covid. March 27, 2021. Kidney Plus Conference. Mexico (Virtual).

5. Introduction to Interventional Nephrology. January 23, 2021. Enduring educational lecture. International Society of nephrology.

6. Safety rules for IN procedures: radiation, sedation, infection prevention. January 23, 2021. Enduring educational lecture. International Society of nephrology.

7. The current technology: An ace up your sleeve. Session on: When the vascular bed is exhausted: How far does current technology take us. November 5, 2020. GEMAV. Spanish Multidisciplinary Group for Vascular Access. Barcelona, Spain (Virtual).

8. Updates in management of anemia of CKD. Ethiopia-Virtual. Global One Health Summer Institute. August 26, 2020


9. Strategies to avoid catheters. Annual Dialysis Conference. Egyptian Society of

Nephrology. October 9, 2019. Cairo, Egypt.

10. Preserving arteries and veins for AV access. Annual Dialysis Conference.

Egyptian Society of Nephrology. October 9, 2019. Cairo, Egypt.

11. Endovascular procedures for vascular access. Annual Dialysis Conference

Workshop. Egyptian Society of Nephrology. October 9, 2019. Cairo, Egypt.

12. Optimal management of central vein disease in hemodialysis patient. May 25,

2019. KSN 2019. 39th Annual Meeting of the Korean Society of Nephrology.

Seoul, South Korea.

13. Interventional Nephrology: Safety Matters. May 24, 2019. KSN 2019. 39th

Annual Meeting of the Korean Society of Nephrology. Seoul, South Korea.

14. Optimal timing and type of pre-dialysis access creation remains a mystery. May

24, 2019. KSN 2019. 39th Annual Meeting of the Korean Society of

Nephrology. Seoul, South Korea.

15. Considerations for an optimal site for AVF/Graft. September 26, 2018. Kracon

2018. Dialysis Access Pre conference symposium. Mombasa, Kenya.

16. The science behind failing arterial venous fistulae: Is there an exit strategy?

September 26, 2018. Kracon 2018. Dialysis Access Pre conference

symposium. Mombasa, Kenya.

17. Panel discussion: Catheter based and non-catheter based hemodialysis

access- pros and cons. September 26, 2018. Kracon 2018. Dialysis Access

Pre conference symposium. Mombasa, Kenya.

18. Rejuvenating nephrology training: Integrating interventional nephrology.

September 27, 2018. Kracon 2018. Dialysis Access Pre conference

symposium. Mombasa, Kenya.

19. Managing dysfunctional hemodialysis catheter. July 21, 2018. AVATAR

Scientific Meeting. New Delhi, India.


20. Hemodynamic impact of AV access. July 21, 2018. AVATAR Scientific Meeting.

New Delhi, India.

21. Safety matters. Radiation, analgesics, contrast. July 21, 2018. AVATAR

Scientific Meeting. New Delhi, India.

22. Clinical decision tree of central venous stenosis treatment: Balloon? Stent

or...?s. September 2017. Beijing, China.

23. Management of central vein stenosis. January 2017. All India Institute of

Medical Sciences. New Delhi, India.

24. Swollen arm: Is it central vein stenosis? February 3-4 2017. 1st Interventional

and Critical Care Nephrology Group Meeting, SGPGIMS, and first meeting of

the society of Indian Society of Interventional & Critical Care Nephrology.

Lucknow, India.

25. Clinical monitoring of vascular access dysfunction. February 3-4 2017. 1st

Interventional and Critical Care Nephrology Group Meeting, SGPGIMS, and

first meeting of the society of Indian Society of Interventional & Critical Care

Nephrology. Lucknow, India.

26. Interventional Nephrology Workshop. February 4. 1st Interventional and Critical

Care Nephrology Group Meeting, SGPGIMS, and first meeting of the society

of Indian Society of Interventional & Critical Care Nephrology. Lucknow, India.

27. International Society of Nephrology Educational Ambassador. Interventional

Nephrology. March 10-18, 2016. Global Hospital. Mumbai, India.

28. Central vein stenosis. November 29, 2015. Dialysis Vascular Access

Symposium & Workshop. Kuwait Nephrology Association. Kuwait, UAE.

29. Post-operative hemodialysis vascular access evaluation and long term

surveillance. November 29, 2015. Kuwait Nephrology Association. Kuwait,

UAE.


30. Tunneled Catheter Design, Function and Performance. November 29, 2015.

Dialysis Vascular Access Symposium & Workshop. Kuwait Nephrology

Association. Kuwait, UAE.

31. Catheter Lock Solutions. Nov 29, 2015. Dialysis Vascular Access Symposium

& Workshop. Kuwait Nephrology Association. Kuwait, UAE.

32. Type of vascular access and current outcomes. August 14, 2015. Korean

Society of Nephrology, Seoul.

33. Dialysis access training program. August 14, 2015. Korean Society of

Nephrology, Seoul.

34. Endovascular interventions for central vein stenosis. August 14, 2015. Korean

Society of Nephrology, Seoul.

35. AVF Maturation: Approach to planning and intervention. Indovasc Symposium.

March 21, 2015. Bengaluru, India.

36. Tunneled dialysis catheter avoidance strategies. Indovasc Symposium. March

21, 2015. Bengaluru, India.

37. Groundbreaking clinical trials in dialysis vascular access. Indovasc Symposium.

March 21, 2015. Bengaluru, India.

38. Endovascular interventions for central vein stenosis. Dialysis Access

Symposium. August 14, 2015. Seoul, South Korea.

39. Dialysis access training program. August 14, 2015. Seoul, South Korea.

40. Types of vascular access and current outcomes. August 14, 2015. Seoul,

South Korea

41. Lifeline for lifetime. INCON, Mumbai Nephrology Group/ Indian Society of

Nephrology West Zone/ASDIN. October 9, 2014. Mumbai, India.

42. Outcomes and safety of endovascular procedures. INCON, Mumbai

Nephrology Group/ Indian Society of Nephrology West Zone/ASDIN. October

9, 2014. Mumbai, India.


43. Erythropoietin in non-kidney disease. INCON, Mumbai Nephrology Group/

Indian Society of Nephrology West Zone/ASDIN, October 9, 2014. Mumbai,

India.

44. Dysfunctional tunneled catheter- Non-infective causes & management. INCON,

Mumbai Nephrology Group/ Indian Society of Nephrology West Zone/ASDIN,

October 10, 2014. Mumbai, India.

45. Interventional Nephrology Workshop. INCON, Mumbai Nephrology Group/

Indian Society of Nephrology West Zone/ASDIN, October 10, 2014. Mumbai,

India.

46. Interventional Nephrology. February 5, 2014. Grand Rounds, All India Institute

of Medical Sciences, New Delhi, India.

47. Antibiotic lock, what is new? February 1, 2014. CME on CE on Interventional

and Lab Nephrology. February 1, 2, 2014. SGPGIMS. Lucknow, India.

48. PD catheter complications. February 1, 2014. CME on CE on Interventional

and Lab Nephrology. February 1, 2, 2014. SGPGIMS. Lucknow, India.

49. Central vein stenosis. February 1, 2014. CME on CE on Interventional and Lab

Nephrology. February 1, 2, 2014. SGPGIMS. Lucknow, India.

50. Interventional Nephrology global perspective. February 1, 2014. CME on CE

on Interventional and Lab Nephrology. February 1, 2, 2014. SGPGIMS.

Lucknow, India.

51. Workshop on Interventional Nephrology. February 2, 2014. CME on CE on

Interventional and Lab Nephrology. February 1, 2, 2014. SGPGIMS. Lucknow,

India.

52. Management of central vein stenosis. ISN Education Update Web Presentation.

November 22, 2013.

53. Tunneled dialysis catheter: Design, function, and performance. December 29,

2012. Jeddah, KSA.


54. Dialysis Access Surveillance: The guidelines and the evidence. December 29,

2012. Jeddah, KSA.

55. Catheter Lock Solutions: What is the evidence? December 29, 2012. Jeddah,

KSA.

56. Catheter related Bacteremia: Evidence Based management and guidelines.

December 29, 2012. Jeddah, KSA.

57. Workshops: Physical examination and Tunnelled catheter placement model.

December 29, 2012. Jeddah, KSA.

58. Role of angioplasty in the management of dialysis vascular access. December

27, 2012. Emirates Society of Nephrology. Dubai, UAE.

59. Managing Complications of Peritoneal Dialysis Catheter. December 27, 2012.

Emirates Society of Nephrology. Dubai, UAE.

60. Interventional Nephrology Workshop. December 28, 2012. Emirates Society of

Nephrology. Dubai, UAE.

61. Tunneled dialysis catheters: Good, Bad and Ugly. September 21, 2012. CME

Conference for East Siberia and Far East Region. Russian Dialysis Society.

Vladivostok, Russia.

62. Primary and Secondary AV fistula. September 21, 2012. CME Conference for

East Siberia and Far East Region. Russian Dialysis Society. Vladivostok,

Russia.

United States:

1. Anemia of CKD: A changing perspective based on the HIF pathway. May 19, 2021. Columbus, Ohio (Virtual).

2. The Emerging Role of HIF Inhibitors for Management of Anemia in CKD. April 6, 2021. National Kidney Foundation 2021 Spring Clinical Meetings.

3. Chair: Interactive Workshop: Dialysis Vascular Access Related Emergencies -


Clinical Case Discussion. April 8, 2021. National Kidney Foundation 2021 Spring Clinical Meetings.

4. Chair, Session on Anemia of CKD. March 7, 2021. National Kidney Foundation 2021 Spring Clinical Meetings.

5. New Methods of arteriovenous access creation. Annual Dialysis Conference 2021. March 5

6. Chair, National Kidney Foundation Kidney and Transplant Symposium March 2, 2021

7. Keynote Address: Finding solutions: Evolutions in Kidney Care. March 2, 2021.

8. Panel of mentoring of nephrology fellows. Panel member. February 18, 2021 9. COVID-19 and Vascular Access Practices. ASDIN Annual meeting Februrary

18, 2021. 10. Presidential Address: . ASDIN Annual meeting February 17, 2021. 11. Anemia of CKD: A changing perspective based on the HIF pathway.

December 2, 2020. Virtual. 12. CKD: Recognition and Management. November 18, 2020. Veteran Affairs

Grand Rounds. Fresno. 13. Targeting Hypoxia-Inducible Factor in the Management of Anemia in Patients

with CKD: An Update on Emerging Therapies. September 30, 2020. Louisiana State University Grand Rounds. Virtual CME lecture

14. Anemia of CKD: A changing perspective based on the HIF pathway. Virtual. July 30, 2020.

15. New horizons in treatment of kidney disease: The future is here! May 28, 2020.

OH State University Wexner Medical Center, Columbus, OH.

16. Management of anemia in patient with chronic kidney disease. Challenges and

emerging strategies. March 28, 2020. Live Virtual NKF Spring Clinical Meetings

Symposium.

17. On shaky grounds: Diabetic kidney disease. Virtual. Lectures on March 24,25,

April 1 and 4.


18. Anemia of CKD: New paradigm. February 22, 2020. Medicine Grand Rounds.

Veterans Administration Hospital. Fresno, CA.

19. New KDOQI Guidelines- Managing implications of increase in catheter use.

February 21, 2021. ASDIN annual meeting. Las Vegas.

20. How to prolong patency of vascular access. February 8, 2020. Annual Dialysis

Conference. Kansas City.

21. Exploring emerging strategies in the management of anemia in chronic kidney

disease. December 10, 2019. Midday Symposium, 2019 ASHP Midyear

Clinical Meeting and Exhibition. Las Vegas.

22. Anti-platelet agents and vascular access. September 23, 2019. International

Society of Hemodialysis Conference. Chicago, Il.

23. Dosing of advanced APT agents for ACS in HD. September 23, 2019.

International Society of Hemodialysis Conference. Chicago, Il.

24. Caring for vascular access for home hemodialysis. Sep 23, 2019. Home

Hemodialysis Symposium. Indiana University. Chicago, Il.

25. Chronic Kidney Disease. September 4, 2019. Family Medicine Grand Rounds.

OH State University. Columbus, OH

26. Catheters for acute and chronic hemodialysis. July 31, 2019. Nephrology

Grand Rounds. OH State University. Columbus, OH.

27. Interventional Nephrology: Safety Matters. June 21, 2019. Nephrology Grand

Rounds. OH State University. Columbus, OH.

28. Transitioning from peritoneal dialysis to home hemodialysis: Why, Who, How?

July 19, 2019. Fresenius Medical Care Regional Conference. Columbus, OH.

29. Pathophysiology of anemia in CKD and associated risks and outcomes. May

10, 2019. Anemia in chronic kidney disease: Arming clinicians with meaningful

solutions. NKF 2019 Spring Clinical Meetings. Boston, MA.


30. LOCK-IT-100: An investigational antimicrobial catheter lock solution shown to

reduce life threatening infections in hemodialysis patients. May 10, 2019. Late

Breaking Research Presentation. NKF 2019 Spring Clinical Meetings. Boston,

MA.

31. Strategies to avoid dialysis catheters. March 17, 2019. Annual Dialysis

Conference. Dallas, TX.

32. An update on management of central vein stenosis. March 17, 2019. Annual

Dialysis Conference. Dallas, TX.

33. Urgent vascular access for HD: Early cannulation AVG or tunneled CVC. March

17, 2019. Annual Dialysis Conference. Dallas, TX.

34. Catheters for acute and chronic HD. March 17, 2019. Annual Dialysis

Conference. Dallas, TX.

35. Vessel Preservation. March 17, 2019. Annual Dialysis Conference. Dallas, TX.

36. Keeping your kidneys strong. Sneh Community. Columbus, Ohio. Feb 24, 2019

37. Ultrasound Workshop. Renal Biopsy. Jan 14 2019. ASDIN Annual Meeting.

Atlanta, GA.

38. Chronic Kidney Disease. September 11, 2018. IM Residents lecture. Columbus,

OH.

39. Treating anemia of chronic kidney disease: Challenges and new approaches.

June 15, 2018. Internal Medicine Grand Rounds. UCSF, Fresno, CA.

40. Chronic Kidney Disease. June 13, 2018. Family Medicine Grand Rounds.

Columbus, OH.

41. Anemia in chronic kidney disease: Emerging management strategies. May 25,

2018. Nephrology Grand Rounds. Columbus, OH.

42. Interventional Nephrology training: Impact, opportunities, approach. May 5,

2018. Nephrology Training Program Directors Retreat. Chicago, Il

43. Cardiovascular risk in patients with chronic kidney disease (CKD): The impact


of anemia. Enduring CME Program. April 13, 2018. NKF Spring Clinical

Meetings. Austin, Tx.

44. Cardiovascular Risk in Patients with Chronic Kidney Disease (CKD): The

Impact of Anemia. Symposium. April 13, 2018. NKF Spring Clinical Meetings.

Austin, Tx.

45. Symposium Chair. National Kidney Foundation 2018 Kidney & Transplant

Symposium. March 20-21, 2018. Columbus OH.

46. AV fistula updates. March 20, 2018. National Kidney Foundation 2018 Kidney

& Transplant Symposium. Columbus OH.

47. Session Chair. Fundamentals of extracorporeal therapy: Hemodialysis Access.

March 3, 2018. Annual Dialysis Conference. Orlando, Fl.

48. The arteriovenous fistula: Basics and beyond. Annual Dialysis Conference.

Orlando, Fl.

49. Prophylactic angioplasty of AVF: What does evidence tell us? Annual Dialysis

Conference. Orlando, Fl.

50. Panelist. Hemodialysis: Learn from your colleagues panel discussion: Practical

solutions to practical problems in HD. March 4, 2018. Annual Dialysis

Conference. Orlando, Fl.

51. Session Chair. Roadmap to Dealing with Hemodialysis Catheters and Their

Complications. February 18, 2018. 14th Annual ASDIN Scientific Meeting. Salt

Lake City, Utah.

52. Roadmap to Dealing with Hemodialysis Catheters and Their Complications:

Catheter-associated Central vein thrombosis and what to do about It? February

18, 2018. 14th Annual ASDIN Scientific Meeting. Salt Lake City, Utah

53. Treating anemia of chronic kidney disease: Current and emerging therapies.

December 8, 2017. Nephrology Grand Rounds. Columbus, OH


54. Prophylactic PTA for AV fistula venous stenosis. September 9, 2017.

International Society of Hemodialysis. Hemodialysis University, Chicago, Il.

55. Chronic kidney disease. IM Resident Conference. Aug 15, 2017. Columbus,

OH.

56. Dialysis access. Nephrology Grand Rounds. July 10, 2017. Columbus, OH.

57. Managing anemia and chronic kidney disease: Considerations for

cardiovascular risk. April 19, 2017. NKF Spring Clinical Meetings. Orlando, Fl.

58. Co-Chair. Basics of Vascular Access: The Practical Essentials. April 10, 2017.

NKF Spring Clinical Meetings. Orlando, Fl.

59. How can my patient start dialysis with AVF and not a catheter? Basics of

Vascular Access: The Practical Essentials. April 10, 2017. NKF Spring Clinical

Meetings. Orlando, Fl.

60. Frequent flyer with congestive heart failure- Could it be vascular access related?

Basics of Vascular Access: The Practical Essentials. April 10, 2017. NKF

Spring Clinical Meetings. Orlando, Fl.

61. My left arm is getting heavier-Is there a problem? Basics of Vascular Access:

The Practical Essentials. April 10, 2017. NKF Spring Clinical Meetings. Orlando,

Fl.

62. The massively swollen arm: Management options. April 11, 2017. NKF Spring

Clinical Meetings. Orlando, Fl.

63. The Conflict of Conformance and Caring. March 18, 2017. RPA Annual Meeting.

Nashville, TN.

64. Physical exam- Hands-on procedures for nephrologists and fellows. February

10, 2017. ASDIN PreCourse. New Orleans, LA.

65. Case discussions– What vascular access to plan in CKD/ESRD patients.

February 10, 2017. ASDIN Pre-Course. New Orleans, LA.


66. Optimizing Productivity. Session Co-Chair. February 10, 2017. ASDIN

PreCourse. New Orleans, LA.

67. Ground breaking trials in dialysis vascular access. October 3, 2016. Renal

Grand Rounds. Hofstra North Shore LIJ School of Medicine. New Jersey, NJ.

68. Chronic kidney disease. December 28, 2016. Family Medicine Grand Rounds.

Ohio State University. Columbus, OH.

69. Tunneled catheter avoidance- Seven simple strategies. September 7, 2016.

Island Peer Review Organization Webinar.

70. Tunneled catheter avoidance- Seven simple strategies. August 27, 2016. Ohio

State Nephrology Symposium. Columbus, OH.

71. Chronic kidney disease. June 28, 2016. Internal Medicine Resident Conference.

Ohio State University. Columbus, OH.

72. Advanced surveillance techniques. February 19, 2016. ASDIN. Phoenix, AZ.

73. Kidney biopsy procedure. February 18, 2016. Fellows Workshop. ASDIN.

Phoenix, AZ.

74. Ground breaking clinical trials in dialysis vascular access. November 19, 2015.

Nephrology Grand Rounds. University of Arizona, Tucson, AZ.

75. Ground breaking clinical trials in dialysis vascular access. September 30, 2015.

Nephrology Grand Rounds. Louisiana State University. Shreveport, LA.

76. Failing AV access should be treated with non-surgical means. November 13,

2015. Controversies in Vascular Diseases Conference. Columbus, OH.

77. AVF options in elderly CKD patients: AVF or AVG. October 3, 2015. 2nd Annual

John C. McDonald Transplant and Dialysis Access Symposium. Shreveport,

LA.

78. Moderator. Abstract Presentations, February 14, 2015. ASDIN Annual

Scientific Meeting. Orlando, Fl.


79. Non maturing pre-ESRD AVF- When to stop. February 14, 2015. ASDIN

Annual Scientific Meeting. Orlando, Fl.

80. Fellows Pre-Course. Renal biopsy hands-on session. February 13, 2015.

ASDIN Annual Scientific Meeting. Orlando, Fl.

81. Fellows Pre-Course. Physical exam hands-on session. February 13, 2015.

ASDIN Annual Scientific Meeting. Orlando, Fl.

82. Chronic kidney disease. February 8, 2015. IM Residents Conference.

Columbus, OH.

83. Dialysis access planning and dysfunction. February 6, 2015. Nephrology Grand

Rounds. Columbus, OH.

84. Managing access dysfunction. February 1, 2015. A Comprehensive Course in

Hemodialysis (pre-conference session). Annual Dialysis Conference 2015.

New Orleans, LA.

85. Access selection and planning. February 1, 2015. A Comprehensive Course in

Hemodialysis (pre-conference session). Annual Dialysis Conference 2015.

New Orleans, LA.

86. Anemia management in kidney disease: Optimizing treatment response.

November 15, 2014. Educational Symposium. ASN Kidney Week 2014.

Philadelphia, PA.

87. Meet the Experts Panel for Residents. A program of ASN’s Kidney STARS.

November 13, 2014. ASN Kidney Week. Philadelphia PA.

88. Optimal Iron therapy for optimal ESA response in HD-CKD. Oct 31, 2014.

Nephrology Grand Rounds. Columbus, OH.

89. Access for home hemodialysis. June 25, 2014. Nephrology Grand Rounds.

Columbus, OH.

90. Anemia in chronic kidney disease and cancer. Use of erythropoietin analogs.



91. Recognition of common acid base disorders. April 11, 2014. Nephrology Grand

Rounds. Columbus OH.

92. Moderator. Economics of Vascular Access Session. Feb 22, 2014. ASDIN

2014. Phoenix, AZ.

93. Debate. Con- Point counterpoint: Access selection in the context of ESRD

Network mandates vs. what about the patient’s interest? Feb 22. 2014. ASDIN

2014. Phoenix, AZ.

94. Physical examination of vascular access. Fellows workshop. Feb 22, 2014.

ASDIN, Phoenix AZ.

95. Secondary AV fistula timing. Nov 13, 2013. Interventional Nephrology Pre

course. Asn Kidney Week. Atlanta, GA.

96. Management of Anemia. Nov 14, 2013. ASN Kidney Week. Atlanta, GA

97. Emerging therapies for patients with anemia of chronic kidney disease. October

11, 2013. Nephrology Grand Rounds. Columbus, OH.

98. Access complications. Sep 27, 2013. University of Cincinnati Hemodialysis

Vascular Access Symposium. Cincinnati, OH.

99. Coll-R wraps. Sep 28, 2013. University of Cincinnati Hemodialysis Vascular

Access Symposium. Cincinnati, OH.

100. Emerging therapies for anemia of CKD. Sep 18, 2013. Amgen Staff Lecture.

Thousand Oaks, CA.

101. Central vein stenosis. Sep 6, 2013. Nephrology Grand Rounds. Henry Ford

Hospital. Detroit, MI.

102. Dialysis vascular access. July 15, 2013. Nephrology Grand Rounds.

Columbus OH.

103. Interventional Nephrology education and training: Challenges, opportunities

and future directions. May 8, 2013. Nephrology Grand rounds. Brigham and

Women’s Hospital. Boston, MA.


104. The undiagnosed renal patient in crisis. June 20, 2013. OSU Center for EMS

and the Emergency Department at OSU Hospital East. Columbus, OH.

105. Enduring CME/CE activity. Hemoglobin variability: Individualization of

anemia management for the patient with End Stage Renal Disease. April 3,

2013. Based on the Satellite Symposium, NKF Spring Clinical Meeting 2013.

Lake Buena Vista, Fl.

106. Hemoglobin variability: Individualization of anemia management for the

patient with End Stage Renal Disease. April 3, 2013. Satellite Symposium, NKF

Spring Clinical Meeting 2013. Lake Buena Vista, Fl.

107. The failing access: When should I send patient for secondary AV fistula?

April 2, 2013. NKF SCM Interventional Nephrology Pre-course and Hands-On

Workshops. Orlando, FL.

108. Anticoagulation and vascular access. April 2, 2013. NKF Interventional

Nephrology Pre-course and Hands-On Workshops. Orlando, FL.

109. Effective utilization of available treatment options for patients with anemia of

ESRD. March 28, 2013. Fellows Conference, OSU. Columbus, OH.

110. Catheter lock solutions: What is new? March 9, 2013. Annual Dialysis

Conference, Seattle, WA.

111. Clinical monitoring of vascular access patency and function. March 9, 2013.

Annual Dialysis Conference, Seattle, WA.

112. Moderator. Access Selection and Preservation Session. February 16 2013.

ASDIN. Washington, DC.

113. Moderator. New Initiatives for ASDIN Session. February 16 2013. ASDIN.

Washington, DC.

114. Tunneled dialysis catheters: Good, bad and ugly. October 29, 2012.

Interventional Nephrology Pre-course. ASN Kidney Week. San Diego, CA.


115. Recognition of common acid-base disorders. October 26, 2012. Update in

Internal Medicine. Mount Nittany Medical Center. College Station, PA.

116. Nephrolithiasis. September 23, 2012. State conference. American

Association of Physicians from India. Columbus, OH.

117. Interventional Nephrology Education: Challenges and opportunities.

September 11, 2012. Nephrology Grand Rounds. University of Cincinnati.

Cincinnati, OH.

118. Tunneled dialysis catheters: Good, bad and ugly. October 30, 2012.

Interventional Nephrology for the General Nephrologist. ASN Kidney Week

2012 Early Program. San Diego, CA.

119. Anemia in CKD stage 5: Balancing morbidity, mortality, and quality of life.

May 10, 2012. Durable web program based on presentation at the National

Kidney Foundation 2012 Spring Clinical Meetings. Washington, DC.

120. Anemia in CKD stage 5: Balancing morbidity, mortality, and quality of life.

May 10, 2012. National Kidney Foundation 2012 Spring Clinical Meetings.

Washington, DC.

121. Mineral bone disorders in chronic kidney disease. March 16, 2012.


122. Heparin bonded ePTFE grafts: Do they have a place In vascular access?

Feb 25, 2012. ASDIN. New Orleans, LA.

123. Intervention- Managing mineral disturbances across the CKD-MBD

continuum. From stage 4 to hemodialysis. Jan 12, 2012. CME Program. Jacobi

Medical Center, Bronx, NY.

124. Mineral bone Disorders in chronic kidney disease. Dec 20, 2011. IM

Residents Conference. Columbus, OH.

125. Protecting the kidney in people with Type 2 diabetes: A playbook for tackling

team care. December 14, 2011. CME Program. Columbus, OH.



continuum. From stage 4 to hemodialysis. December 15, 2011. CME Program.

St. Louis, MO



Nashville, TN



Cleveland, OH

129. Management of central vein stenosis. Nov 9, 2011. ASN Kidney Week 2011.

Philadelphia PA.

130. Venous stents: Pro. There is a role for endovascular stent in vascular access.

April 26, 2011. NKF SCM 2011. Las Vegas, NV.

131. Central vein stenosis with arm and/or breast swelling: What is the sequence

of treatment? February 10, 2011. ASDIN 2011. Las Vegas, NV.

132. What is new in Nephrology? November 9, 2010. Nephrology Updates.

Mansfield, OH.

133. Catheter: A dying access. November 2010. Renal Network 4 Conference.

Philadelphia, PA.

134. Fistula First: Impact on AVF, AVG and catheters. An Update. February 8,

2010. ASDIN. Orlando, Fl.

135. Vascular Access: Achieving outcomes through QAP. January 11, 2010.

Renal Network 10 Webex.

136. Cardiovascular complications of chronic renal disease. November 6, 2009.

Fall Medicine Update. Mount Nittany Medical Center. College Station, PA.

137. Dialysis access. July 10, 2009. Nephrology Grand Rounds. Columbus, OH.


138. Secondary AV fistula. March 26, 2009. Interventional nephrology Pre-course.

NKF SCM 2009. Nashville, TN.

139. CKD, calcification and mortality: Role of minerals. April 18, 2008. Genzyme

Headquarters. Boston, MA.

140. Vascular calcification, stiffness and kidney: Between rock and hard place!

April 12, 2009. Nephrology grand rounds. Columbus, OH.

141. The swollen arm: Diagnosis and treatment of central vein stenosis. April 3,

2008. NKF SCM 2008. Dallas, TX.

142. Secondary hypertension. November 27, 2007. Nephrology Grand Rounds.

Columbus, OH.

143. Renoprotection in diabetic nephropathy: Glycemic control, BP control and

angiotensin inhibition. August 24, 2007. Florida Medical Association.

144. Family Practice Board Review Course in Nephrology. June 18, 2007.

Columbus, OH.

145. Kidney Stones. May 6, 2007. Nephrology Grand Rounds. Columbus, OH.

146. Anemia of CKD: Extended Dosing of ESAs. May 3, 2007. Grand Rounds.

New Jersey.

147. Anemia of CKD: New iron therapies. April 11, 2007. NKF SCM. Orlando, Fl.

148. Secondary Hyperparathyroidism. November 8, 2006. Fresenius Medical

Care. Columbus, OH.

149. Nuts and Bolts of interventional nephrology. Interventional Nephrology

Workshop. September 6, 2006. University of Louisville, KY.

150. Renal artery stenosis: An approach to diagnosis and management. May 24,

2006. Medicine Grand Rounds. Zanesville, OH.

151. Phosphorus binding: What is new? May 5, 2006. NKF Kidney and Transplant

Symposium. Columbus, OH.


152. Management of CKD anemia. April 14, 2006. American Medical director

Association Conference. New Orleans, LA.

153. CARDIOVASCULAR DISEASE AND THE KIDNEY. January 12, 2005. OH

State Cardiology Symposium. Columbus, OH.

154. Pathogenesis and Approach to Management of Secondary

Hyperparathyroidism. December 15, 2005. Fresenius Medical Care staff

meeting. Columbus, OH.

155. Activation of Kidney Care: Evidence for Intervention in the Continuum of

Care for CKD and Secondary Hyperparathyroidism. December 6, 2005. The

2005 Case-Based Educational Lecture Series (ELS). Sponsored by The Johns

Hopkins University School of Medicine, Montefiore Medical Center, and the

University of Tennessee College of Pharmacy, in association with the National

Kidney Foundation (NKF). Columbus, OH.

156. Anemia In Chronic Kidney Disease. November 1, 2005. Medicine Grand

Rounds. Licking Memorial Hospital. Newark, OH.

157. UPDATES IN CKD: ANEMIA SECONDARY Hyperparathyroidism. October

28, 2005. ?

158. Early Identification and Treatment of Chronic Kidney Disease. October 25,

2005. Milwaukee, Wisconsin.

159. New Methods to bind phosphorus in CKD. October 2005. ?

160. Early Identification and Treatment of Chronic Kidney Disease. September 10,

2005. Atlanta, GA.

161. Agarwal Research. August 24, 2005. Clinical Research Symposium. OH

State University.

162. Anemia in kidney disease. August 1, 2005

163. Acidosis. July 22, 2005.


164. Hypertensive urgencies and emergencies. July 15, 2005. Fellows

conference.

165. Acute renal failure. July 7, 2005.

166. Hypertension. May 23, 2005. Integrated biomedical graduate program. OH

State University.

167. Hypertension and cardio renal continuum. May 24, 2005. Mednet webcast.

168. Focus on AV Fistula: Improving AVF Rates. April 27, 2005. Central OH

Medical Directors Coalition.

Department of Health. Columbus, OH.

169. Chronic Kidney Disease. March 31, 2005. Medicine Grand Rounds. VA

Clinic. Columbus, OH.

170. Cardiovascular Disease case studies. March 23, 2005. Conference on

Anemia. Johns Hopkins

University. Baltimore, MD.

171. Cardiorenal continuum. Feb 17, 2005.

172. Acidosis. Feb 17, 2005.

173. TREATING HYPERTENSION: Role of Combination Therapy. Feb 8, 2005.

174. Renal artery stenosis: An Approach To Diagnosis and Management.

February 7, 2005. Medicine

Grand Rounds. Zanesville, OH.

175. Chronic Kidney Disease. January 27, 2005. Grand Rounds. Veterans

Administration Hospital.

Wright Patterson Air Force Base. Dayton, OH.

176. VASCULAR ACCESS: Why not Fistula First? December 2, 2004. Fresenius

Medical Care Medical

Directors Meeting. Columbus, OH.


177. Chronic Kidney Disease. October 14, 2004. Mednet Presentation. Columbus,

OH

Anemia in kidney disease. September 2004.

ANIL K. AGARWAL MBBS, MD, FACP, FASN, FNKF, FASDIN 2615 E ...

Documents

Transcript of ANIL K. AGARWAL MBBS, MD, FACP, FASN, FNKF, FASDIN 2615 E ...